Form 8-K

8-K — Janus Living, Inc.

Accession: 0001104659-26-070511

Filed: 2026-06-04

Period: 2026-06-02

CIK: 0002100805

SIC: 6798 (REAL ESTATE INVESTMENT TRUSTS)

Item: Entry into a Material Definitive Agreement

Item: Financial Statements and Exhibits

Documents

8-K — tm2614872d11_8k.htm (Primary)

EX-1.1 — EXHIBIT 1.1 (tm2614872d11_ex1-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2614872d11_8k.htm · Sequence: 1

false

0002100805

2026-06-02

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 2, 2026

Janus Living, Inc.

(Exact name of registrant as specified in its

charter)

Maryland

001-43206

41-2996951

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

4600

South Syracuse Street, Suite 500

Denver, CO 80237

(Address of principal executive offices) (Zip

Code)

(720)428-5050

(Registrant’s telephone number, including

area code)

N/A

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under

the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under

the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under

the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under

the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on

which registered

Class A-1 Common Stock,

$0.01 par value

JAN

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging

growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any

new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 Entry into a Material Agreement

On June 4, 2026, Janus Living, Inc. (the “Company” and,

unless the context otherwise requires, together with its consolidated subsidiaries, “we,” “us,” or “our”)

closed its registered underwritten public offering (the “Offering”) of 25,000,000 shares of Class A-1 common stock, $0.01

par value per share (the “Class A-1 Common Stock”), pursuant to the Company’s registration statement on Form S-11 (File

No. 333-296384) (the “Registration Statement”). In addition, the Company granted the underwriters a 30-day option to purchase

up to an additional 3,750,000 shares of Class A-1 Common Stock.

Underwriting Agreement

In connection with the Offering, the Company entered into the Underwriting

Agreement, dated June 2, 2026, by and among the Company, Janus Living OP, LLC (the “Operating Company”), Healthpeak Investment

Management, LLC, as external manager to the Company (the “Manager”), and BofA Securities, Inc., J.P. Morgan Securities LLC,

RBC Capital Markets, LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (the “Underwriting

Agreement”). The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company,

the Operating Company and the Manager, customary conditions to closing, indemnification obligations of the Company, the Operating Company

and the underwriters, including for liabilities under the Securities Act, certain other obligations of the parties and termination provisions.

The summary above is qualified in its entirety by the text of the Underwriting

Agreement, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)           Exhibits.

The following exhibits are being filed herewith:

No.

Description

1.1

Underwriting Agreement, dated June 2, 2026, among Janus Living, Inc., Janus Living OP, LLC, Healthpeak Investment Management, LLC and BofA Securities, Inc., J.P. Morgan Securities LLC, RBC Capital Markets, LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly

authorized.

JANUS LIVING, INC.

Date: June 4, 2026

By:

/s/ Kelvin O. Moses

Name:

Kelvin O. Moses

Title:

Chief Financial Officer

EX-1.1 — EXHIBIT 1.1

EX-1.1

Filename: tm2614872d11_ex1-1.htm · Sequence: 2

Exhibit 1.1

Execution Version

25,000,000 Shares

Janus Living, Inc.

(a Maryland corporation)

Class A-1 Common Stock

(Par Value $0.01 Per Share)

UNDERWRITING

AGREEMENT

25,000,000 Shares

Janus Living, Inc.

(a Maryland corporation)

Class A-1 Common Stock

(Par Value $0.01 Per Share)

UNDERWRITING AGREEMENT

June 2,

2026

BofA Securities, Inc.

One Bryant Park

New York, New York 10036

J.P. Morgan Securities LLC

270 Park Avenue

New York, New York 10017

RBC Capital Markets, LLC

200 Vesey Street, 8th Floor

New York, New York 10281

Wells Fargo Securities, LLC

500 West 33rd Street, 14th Floor

New York, New York 10001

As Representatives of the several Underwriters

Ladies and Gentlemen:

Janus Living, Inc., a Maryland corporation

(the “Company”), and Janus Living OP, LLC, a Maryland limited liability company (the “Operating Company,”

and together with the Company, the “Transaction Entities”), and Healthpeak Investment Management, LLC, a Delaware limited

liability company and the Company’s external manager (the “Manager”), confirm their respective agreements with

BofA Securities, Inc. (“BofA”), J.P. Morgan Securities LLC (“J.P. Morgan”), RBC Capital Markets,

LLC (“RBC”) and Wells Fargo Securities, LLC (“Wells Fargo”) and each of the other Underwriters named

in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as

hereinafter provided in Section 11 hereof), for whom BofA, J.P. Morgan, RBC and Wells Fargo are acting as representatives (in such

capacity, collectively, the “Representatives”), with respect to (i) the sale by the Company and the purchase by

the Underwriters, acting severally and not jointly, of the respective numbers of shares of Class A-1 common stock, par value $0.01

per share, of the Company (“Class A-1 Common Stock”) set forth in Schedule A hereto and (ii) the grant

by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase

all or any part of 3,750,000 additional shares of Class A-1 Common Stock. The aforesaid 25,000,000 shares of Class A-1 Common

Stock (the “Initial Securities”) to be purchased by the Underwriters and all or any part of the 3,750,000 shares of

Class A-1 Common Stock subject to the option described in Section 2(b) hereof (the “Option Securities”)

are herein called, collectively, the “Securities.”

The Company has filed with the Securities and Exchange

Commission (the “Commission”) a registration statement on Form S-11 (No. 333-296384), including the related

preliminary prospectus or prospectuses, covering the registration of the offer and sale of the Securities under the Securities Act of

1933, as amended (the “1933 Act”). Promptly after execution and delivery of this Agreement, the Company will prepare

and file a prospectus in accordance with the provisions of Rule 430A (“Rule 430A”) of the rules and

regulations of the Commission under the 1933 Act (the “1933 Act Regulations”) and Rule 424(b) (“Rule 424(b)”)

of the 1933 Act Regulations. The information included in such prospectus that was omitted from such registration statement at the time

it became effective but that is deemed to be part of such registration statement at the time it became effective pursuant to Rule 430A(b) is

herein called the “Rule 430A Information.” Such registration statement, including the amendments thereto, the

exhibits thereto and any schedules thereto, at the time it became effective, and including the Rule 430A Information, is herein called

the “Registration Statement.” Any registration statement filed pursuant to Rule 462(b) of the 1933 Act Regulations

is herein called the “Rule 462(b) Registration Statement” and, after such filing, the term “Registration

Statement” shall include the Rule 462(b) Registration Statement. Each prospectus used prior to the effectiveness of the

Registration Statement, and each prospectus that omitted the Rule 430A Information that was used after such effectiveness and prior

to the execution and delivery of this Agreement, is herein called a “preliminary prospectus.” The final prospectus,

in the form first furnished to the Underwriters for use in connection with the offering of the Securities, is herein called the “Prospectus.”

For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment

or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering,

Analysis and Retrieval system or any successor system (“EDGAR”).

As used in this Agreement:

“Applicable Time”

means 5:45 P.M., New York City time, on June 2, 2026 or such other time as agreed by the Company and the Representatives.

“General

Disclosure Package” means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable Time, the most

recent preliminary prospectus included in the Registration Statement that is distributed to prospective investors prior to the Applicable

Time and the information included on Schedule B-1 hereto, all considered together.

“Issuer

Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433 of the 1933 Act

Regulations (“Rule 433”), including without limitation any “free writing prospectus” (as defined in

Rule 405 of the 1933 Act Regulations (“Rule 405”)) relating to the Securities that is (i) required to

be filed with the Commission by the Company, (ii) a “road show that is a written communication” within the meaning of

Rule 433(d)(8)(i) of the 1933 Act Regulations (“Rule 433(d)(8)(i)”), whether or not required to be filed

with the Commission, or (iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) of the 1933 Act Regulations

because it contains a description of the Securities or of the offering of the Securities that does not reflect the final terms, in each

case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company’s

records pursuant to Rule 433(g) of the 1933 Act Regulations.

“Issuer

General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is intended for general distribution to prospective

investors, as evidenced by its being specified in Schedule B-2 hereto.

“Issuer

Limited Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is not an Issuer General Use Free Writing

Prospectus.

“Testing-the-Waters

Communication” means any oral or written communication with potential investors undertaken in reliance on either Section 5(d) of,

or Rule 163B under, the 1933 Act.

“Written

Testing-the-Waters Communication” means any Testing-the-Waters Communication that is a written communication within the meaning

of Rule 405 under the 1933 Act.

The Transaction Entities understand that the Underwriters

propose to make a public offering of the Securities as soon as the Representatives deem advisable after this Agreement has been executed

and delivered.

Section 1.                Representations

and Warranties.

(a)            Representations

and Warranties by the Transaction Entities. Each of the Transaction Entities, jointly and severally, represents and warrants to each

Underwriter as of the date hereof, the Applicable Time, the Closing Time and each Date of Delivery (as defined below), if any, and agrees

with each Underwriter, as follows:

(i)            Registration

Statement and Prospectuses. Each of the Registration Statement and any post-effective amendment thereto has become effective under

the 1933 Act. No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been

issued under the 1933 Act, no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been issued and

no proceedings for any of those purposes have been instituted or are pending or, to the Transaction Entities’ knowledge, contemplated.

The Company has complied with each request (if any) from the Commission for additional information.

Each of the Registration Statement and

any post-effective amendment thereto, at the time it became effective, the Applicable Time, the Closing Time and any Date of Delivery,

complied and will comply in all material respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary

prospectus, the Prospectus and any amendment or supplement thereto, at the time each was filed with the Commission, and, in each case,

at the Applicable Time, the Closing Time and any Date of Delivery, complied and will comply in all material respects with the requirements

of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus, the Prospectus and any amendment or supplement thereto delivered

to the Underwriters for use in connection with the offering of the Securities was or will be identical to the electronically transmitted

copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

(ii)           Accurate

Disclosure. Neither the Registration Statement nor any post-effective amendment thereto, at its effective time, on the date hereof,

at the Closing Time or at any Date of Delivery, contained, contains or will contain an untrue statement of a material fact or omitted,

omits or will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading.

At the Applicable Time, the Closing Time and any Date of Delivery, neither (A) the General Disclosure Package nor (B) any individual

Issuer Limited Use Free Writing Prospectus, when considered together with the General Disclosure Package, included, includes or will include

an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements

therein, in the light of the circumstances under which they were made, not misleading. Neither the Prospectus nor any amendment or supplement

thereto, as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Time or at any

Date of Delivery, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a

material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.

The representations and warranties in

this subsection (ii) shall not apply to statements in or omissions from the Registration Statement (or any amendment thereto),

the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) made in reliance upon and in conformity with

written information furnished to the Company by any Underwriter through the Representatives expressly for use therein. For purposes of

this Agreement, the only information so furnished shall be the information in the first paragraph under the heading “Underwriting—Commissions

and Discounts,” the information in the second paragraph under the heading “Underwriting—Price Stabilization and Short

Positions” and the information under the heading “Underwriting—Electronic Distribution,” in each case contained

in the Registration Statement, the General Disclosure Package and the Prospectus (collectively, the “Underwriter Information”).

(iii)          Issuer

Free Writing Prospectuses. No Issuer Free Writing Prospectus that has not been superseded or modified conflicts or will conflict with

the information contained in the Registration Statement or the Prospectus, or any preliminary or other prospectus deemed to be a part

thereof that has not been superseded or modified.

(iv)          Testing-the-Waters

Materials. None of the Transaction Entities (A) has engaged in any Testing-the-Waters Communication, (B) has authorized

anyone other than the Representatives to engage in Testing-the-Waters Communications or (C) has distributed any Written Testing-the-Waters

Communications.

(v)           Emerging

Growth Company Status. From the time of the initial confidential submission of the Registration Statement to the Commission through

the date hereof, the Company has been and is an “emerging growth company,” as defined in Section 2(a) of the 1933

Act (an “Emerging Growth Company”).

(vi)          Company

Not Ineligible Issuer. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest

time thereafter that the Transaction Entities, Healthpeak Properties, Inc. (“Healthpeak”), the Manager or another

offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the 1933 Act Regulations) of the

Securities and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405, without

taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered

an ineligible issuer.

(vii)         Independent

Accountants. The accountants who audited or certified the financial statements and supporting schedules included in the Registration

Statement, the General Disclosure Package and the Prospectus are a registered public accounting firm independent of the Company, as required

by the 1933 Act, the 1933 Act Regulations, the Securities Exchange Act of 1934, as amended (the “1934 Act”), the rules and

regulations of the Commission under the 1934 Act (the “1934 Act Regulations”) and the rules and regulations of

the Public Company Accounting Oversight Board.

(viii)        Financial

Statements. The financial statements and any supporting schedules of the Company and its consolidated subsidiaries included in the

Registration Statement, the General Disclosure Package and the Prospectus present fairly in all material respects the consolidated financial

position of the Company and its consolidated subsidiaries as of the dates indicated and the results of operations, stockholders’

equity and cash flows of the Company and its consolidated subsidiaries for the periods specified. Except as otherwise stated in the Registration

Statement, the General Disclosure Package and the Prospectus, said financial statements have been prepared in conformity with U.S. generally

accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods involved. The supporting

schedules of the Company and its consolidated subsidiaries included in the Registration Statement, the General Disclosure Package and

the Prospectus present fairly in all material respects, in accordance with GAAP, the information required to be stated therein. The summary

selected financial data, if any, included in the Registration Statement, the General Disclosure Package and the Prospectus present fairly

in all material respects the information shown therein as of the dates or for the periods indicated and have been compiled on a basis

consistent with that of the audited financial statements included in the Registration Statement, the General Disclosure Package and the

Prospectus. The pro forma financial statements and the related notes thereto, if any, included in the Registration Statement, the General

Disclosure Package and the Prospectus present fairly in all material respects the information shown therein, have been prepared in accordance

with the Commission’s rules and guidelines with respect to pro forma financial statements and have been properly compiled on

the bases described therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein are appropriate

to give effect to the transactions and circumstances referred to therein. Except as included therein, no historical or pro forma financial

statements or supporting schedules are required to be included in the Registration Statement, the General Disclosure Package or the Prospectus

under the 1933 Act or the 1933 Act Regulations. All disclosures contained in the Registration Statement, the General Disclosure Package

or the Prospectus regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the

Commission) comply in all material respects with Regulation G of the 1934 Act, and Item 10 of Regulation S-K of the 1933 Act, to the extent

applicable. The interactive data in eXtensible Business Reporting Language included in the Registration Statement, the General Disclosure

Package and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with

the Commission's rules and guidelines applicable thereto.

(ix)           No

Material Adverse Change. Since the respective dates as of which information is given in the Registration Statement, the General Disclosure

Package and the Prospectus, except as otherwise stated therein or contemplated thereby, (A) there has been no material adverse change

in the condition, financial or otherwise, or in the earnings, business affairs or business prospects of the Transaction Entities and their

subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business (a “Material Adverse Effect”),

(B) there have been no transactions entered into by the Transaction Entities or any of their subsidiaries, other than those in the

ordinary course of business, which are material with respect to the Transaction Entities and their subsidiaries considered as one enterprise

and (C) there has been no dividend or distribution of any kind declared, paid or made by the Transaction Entities on any class of

its capital stock or LLC Interests (as defined below), as applicable.

(x)            Good

Standing of the Company. The Company has been duly incorporated and is validly existing as a corporation in good standing under the

laws of the State of Maryland with corporate power and authority to own, lease and operate its properties and to conduct its business

as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform its obligations

under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in each jurisdiction

in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except

where the failure to so qualify and be in good standing would not have a Material Adverse Effect. The Company is in substantial compliance

with all laws, ordinances and regulations of each state in which it owns properties that are material to the properties and business of

the Company and its subsidiaries considered as one enterprise in such state.

(xi)           Good

Standing of the Operating Company. The Operating Company has been duly formed and is validly existing as a limited liability company

in good standing under the laws of the State of Maryland with power and authority to own, lease and operate its properties and to conduct

its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform

its obligations under this Agreement. The Operating Company is duly qualified as a foreign limited liability company to transact business

and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of

property or the conduct of business, except where the failure to so qualify and be in good standing would not have a Material Adverse

Effect. The Operating Company is in substantial compliance with all laws, ordinances and regulations of each state in which it owns properties

that are material to the properties and business of the Operating Company and its subsidiaries considered as one enterprise in such state.

(xii)          LLC

Agreement of the Operating Company. The amended and restated operating agreement of the Operating Company, dated as of March 17,

2026 (the “LLC Agreement”), is in full force and effect and all of the outstanding membership interests in the Operating

Company (the “LLC Interests”) are duly and validly authorized and issued in accordance with the LLC Agreement. The

LLC Interests to be issued in connection with the Company’s contribution to the Operating Company of the net proceeds from the sale

of the Securities as contemplated in the Registration Statement, the General Disclosure Package and the Prospectus have been duly authorized

for issuance by the Operating Company, and, when issued and delivered pursuant to the LLC Agreement, will be validly issued, and such

issuances by the Operating Company of the LLC Interests are exempt from the registration requirements of the 1933 Act and applicable state

securities, real estate syndication and blue sky laws, and are not in violation of the preemptive or other similar rights of any securityholder

of the Operating Company. At the Closing Time, the aggregate pro forma percentage interests of the Company in the Operating Company will

be as set forth in the Registration Statement, the General Disclosure Package and the Prospectus. The Company is, and at the Closing Time

will be, the sole managing member of the Operating Company. Except as otherwise set forth in the Registration Statement, the General Disclosure

Package and the Prospectus, all outstanding LLC Interests are owned by the Company directly or indirectly, free and clear of any security

interest, mortgage, pledge, lien, encumbrance, restriction on voting or transfer, claim or equity. As of the date of this Agreement, the

Company does, and, as of the Closing Time, the Company will, own at least a majority of the LLC Interests of the Operating Company. No

LLC Interests are reserved for any purpose and there are no outstanding options, warrants, or other rights to purchase, agreements or

other obligations to issue, or rights to convert any obligations into or exchange for, any LLC Interests or other securities of or in

the Operating Company, except as otherwise set forth in the Registration Statement, the General Disclosure Package and the Prospectus

or as may be issued pursuant to employee benefit plans disclosed in the Registration Statement, the General Disclosure Package and the

Prospectus or pursuant to the exercise of convertible or exchangeable securities or options disclosed in the Registration Statement, the

General Disclosure Package and the Prospectus. None of the LLC Interests in the Operating Company have been or will be issued in violation

of the preemptive or other similar rights of any securityholder of the Operating Company. The terms of the LLC Interests conform in all

material respects to statements and descriptions related thereto contained in each of the Registration Statement, the General Disclosure

Package and the Prospectus and such description conforms to the rights set forth in the instruments defining the same.

(xiii)         Good

Standing of Subsidiaries. Each subsidiary of the Company (other than the Operating Company) which is a significant subsidiary (each,

a “Significant Subsidiary”) as defined in Rule 405 of Regulation C of the 1933 Act Regulations has been duly organized

and is validly existing as a corporation, limited liability company or partnership, as the case may be, in good standing under the laws

of the jurisdiction of its organization, has power and authority as a corporation, limited liability company or partnership, as the case

may be, to own, lease and operate its properties and to conduct its business as described in the Registration Statement, the General Disclosure

Package and the Prospectus, and is duly qualified as a foreign corporation, limited liability company or partnership, as the case may

be, to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the

ownership or leasing of property or the conduct of business, except where the failure to so qualify and be in good standing would not

have a Material Adverse Effect. All of the issued and outstanding capital stock of each such corporate Significant Subsidiary has been

duly authorized and validly issued, is fully paid and non-assessable and, except for directors’ qualifying shares, is owned by the

Company, directly or through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, restriction on

voting or transfer, claim or equity; and all of the issued and outstanding partnership or limited liability company interests of each

such Significant Subsidiary which is a partnership or limited liability company, as applicable, have been duly authorized (if applicable)

and validly issued and are fully paid and non-assessable and, except for other partnership or limited liability company interests described

in the Registration Statement, the General Disclosure Package and the Prospectus, are owned by the Company, directly or through subsidiaries,

free and clear of any security interest, mortgage, pledge, lien, encumbrance, restriction on voting or transfer, claim or equity. None

of the outstanding shares of capital stock or other equity interests of any Significant Subsidiary were issued in violation of the preemptive

or other similar rights of any securityholder of such Significant Subsidiary. The only subsidiaries of the Company are the subsidiaries

listed on Exhibit 21.1 to the Registration Statement and certain other subsidiaries which, considered in the aggregate as a single

subsidiary, do not constitute a “significant subsidiary” within the meaning of Rule 1-02 of Regulation S-X promulgated

under the 1934 Act.

(xiv)        REIT

Status. Commencing with its taxable year ending December 31, 2026, the Company has been organized and operated in conformity

with the requirements for qualification and taxation as a “real estate investment trust” (a “REIT”) under

the Internal Revenue Code of 1986, as amended (the “Code”), and its proposed method of operation will enable it to

continue to meet the requirements for qualification and taxation as a REIT under the Code. All statements regarding the Company’s

qualification and taxation as a REIT and descriptions of the Company’s organization and proposed method of operation (inasmuch as

they relate to the Company’s qualification and taxation as a REIT) set forth in the Registration Statement, the General Disclosure

Package and the Prospectus are true, complete and correct summaries of the legal or tax matters described therein in all material respects.

(xv)         Capitalization.

The authorized, issued and outstanding shares of capital stock of the Company are as set forth in the Registration Statement, the General

Disclosure Package and the Prospectus under the caption “Capitalization” (except for subsequent issuances, if any, pursuant

to (i) this Agreement, (ii) reservations, agreements or employee benefit plans referred to in the Registration Statement, the

General Disclosure Package and the Prospectus or (iii) the exercise of convertible or exchangeable securities or options referred

to in the Registration Statement, the General Disclosure Package and the Prospectus). The outstanding shares of capital stock of the Company

have been duly authorized and validly issued and are fully paid and non-assessable. Except as disclosed in the Registration Statement,

the General Disclosure Package and the Prospectus, no shares of capital stock of the Company are reserved for any purpose and there are

no outstanding options, warrants, or other rights to purchase, agreements or other obligations to issue, or rights to convert any obligations

into or exchange for, any shares of capital stock of or in the Company. None of the outstanding shares of capital stock of the Company

were issued in violation of the preemptive or other similar rights of any securityholder of the Company.

(xvi)        Absence

of Violations, Defaults and Conflicts. Neither the Transaction Entities nor any of their subsidiaries is (i) in violation of

its charter, bylaws, partnership agreement, limited liability company agreement or other organizational documents, as the case may be,

or (ii) in default in the performance or observance of any obligation, agreement, covenant or condition contained in any contract,

indenture, mortgage, loan agreement, note, lease or other agreement or instrument to which the Transaction Entities or any of their subsidiaries

is a party or by which they or any of them or their properties or assets may be bound or to which any of the properties or assets of the

Transaction Entities or any of their subsidiaries is subject (collectively, “Agreements and Instruments”) and in which

the violation or default might result, singly or in the aggregate, in a Material Adverse Effect. In the case of the Transaction Entities,

the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein and in the Registration

Statement, the General Disclosure Package and the Prospectus and compliance by the Transaction Entities with their respective obligations

hereunder have been duly authorized by all necessary corporate or other action and will not conflict with or constitute a breach of, or

default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any

properties or assets of the Transaction Entities or any of their subsidiaries pursuant to the Agreements and Instruments (except for such

conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, result

in a Material Adverse Effect), nor will such action result in any violation of (i) the provisions of the charter, bylaws, partnership

agreement, limited liability company agreement or other organizational documents of the Transaction Entities or any of their subsidiaries

or (ii) except to the extent it would not have a Material Adverse Effect, any law, statute, rule, regulation, judgment, order, writ

or decree of any court or governmental agency or body, domestic or foreign having jurisdiction over the Transaction Entities or any of

their subsidiaries or any of their respective properties, assets or operations (each, a “Governmental Entity”). As

used herein, a “Repayment Event” means any event or condition which gives the holder of any note, debenture or other

evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment

of all or a portion of such indebtedness by the Company or any of its subsidiaries.

(xvii)       Dividend

Restrictions. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, no subsidiary

of the Company (including the Operating Company) is currently prohibited, directly or indirectly, under any agreement or other instrument

to which it is a party or is subject, from paying any dividends or making any other distribution on such subsidiary’s capital stock

or other equity interests to owners thereof, from repaying any loans or advances to such subsidiary from the Company or any other subsidiary

of the Company or from transferring any of such subsidiary’s properties or assets to the Company or any other subsidiary of the

Company.

(xviii)      Absence

of Employees. Neither of the Transaction Entities nor any of their respective subsidiaries has any employees, and the Transaction

Entities are not aware of any existing or imminent labor disturbance by the employees of any of their or any subsidiary’s principal

operators, suppliers, manufacturers or contractors, which, in either case, would result, singly or in the aggregate, in a Material Adverse

Effect.

(xix)         Absence

of Proceedings. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there is no

action, suit or proceeding before or by any Governmental Entity now pending, or, to the knowledge of either of the Transaction Entities,

threatened, against or affecting the Transaction Entities or any of their subsidiaries, which is required to be disclosed in the Registration

Statement, the General Disclosure Package or the Prospectus, or would result, singly or in the aggregate, in any Material Adverse Effect,

or would materially and adversely affect the properties or assets thereof, taken as a whole, or which would materially and adversely affect

the consummation of this Agreement or any transaction contemplated hereby or the performance by the Transaction Entities of their obligations

hereunder. All pending legal or governmental proceedings to which either of the Transaction Entities or any of their subsidiaries is a

party or of which any of their properties or assets is the subject which are not described in the Registration Statement, the General

Disclosure Package and the Prospectus, including ordinary routine litigation incidental to the business, are, considered in the aggregate,

not material to either of the Transaction Entities. There are no contracts or documents of either of the Transaction Entities or any of

their subsidiaries which are required to be described in the Registration Statement, the General Disclosure Package or the Prospectus

or to be filed as exhibits to the Registration Statement by the 1933 Act or by the 1933 Act Regulations which have not been so described

and filed as required.

(xx)          Absence

of Further Requirements. No authorization, approval, consent, order or decree of any Governmental Entity is required for the consummation

by the Transaction Entities of the transactions contemplated by this Agreement, or in connection with the offering or sale of the Securities

hereunder, except such as have been already obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the rules of

the New York Stock Exchange, state securities, real estate syndication and blue sky laws or the rules of the Financial Industry Regulatory

Authority, Inc. (“FINRA”).

(xxi)         Authorization

of Underwriting Agreement. This Agreement has been duly authorized, executed and delivered by each of the Transaction Entities.

(xxii)        Authorization

and Description of the Securities. The Securities have been duly authorized for issuance and sale by the Company pursuant to this

Agreement and, when issued and delivered by the Company against payment of the consideration set forth herein, will be validly issued

and fully paid and non-assessable. The issuance of the Securities is not subject to the preemptive or other similar rights of any securityholder

of the Company. The Class A-1 Common Stock conforms in all material respects to all statements relating thereto contained in the

Registration Statement, the General Disclosure Package and the Prospectus and such description conforms to the rights set forth in the

instruments defining the same. No holder of Securities will be subject to personal liability by reason of being such a holder.

(xxiii)       Authorization

and Description of the Class A-2 Common Stock. The outstanding shares of Class A-2 common stock, par value $0.01 per share,

of the Company (“Class A-2 Common Stock” and together with the Class A-1 Common Stock, “Common Stock”)

have been duly authorized and validly issued and are fully paid and non-assessable. The Class A-2 Common Stock conforms in all material

respects to all statements relating thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus

and such description conforms to the rights set forth in the instruments defining the same. No holder of Class A-2 Common Stock will

be subject to personal liability by reason of being such a holder.

(xxiv)      Registration

Rights. There are no persons with registration rights or other similar rights to have any securities registered for sale pursuant

to the Registration Statement or otherwise registered for sale or sold by the Company under the 1933 Act pursuant to this Agreement, other

than those rights that have been disclosed in the Registration Statement, the General Disclosure Package and the Prospectus and have been

waived.

(xxv)       Management

Agreement. The management agreement, dated as of March 19, 2026, among the Company, the Operating Company and the Manager (the

“Management Agreement”), has been duly authorized, executed and delivered by each of the Transaction Entities and is

a valid and legally binding agreement of each of the Transaction Entities, enforceable against each of the Transaction Entities in accordance

with its terms, except to the extent that such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or other

similar laws relating to or affecting creditors’ rights and general principles of equity. All statements relating to the Management

Agreement are true, correct and complete summaries of the matters described therein in all material respects.

(xxvi)      Possession

of Licenses and Permits. The Transaction Entities and their subsidiaries possess such permits, licenses, approvals, consents and other

authorizations (collectively, “Governmental Licenses”) issued by the appropriate governmental agency or body, domestic

or foreign, under applicable law necessary to conduct the business now operated by them, except where the failure so to possess would

not, singly or in the aggregate, result in a Material Adverse Effect. The Transaction Entities and their subsidiaries are in compliance

with the terms and conditions of all Governmental Licenses, except where the failure so to comply would not, singly or in the aggregate,

result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except when the invalidity

of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not, singly or in the

aggregate, result in a Material Adverse Effect. Neither of the Transaction Entities nor any of their subsidiaries has received any notice

of proceedings relating to the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the subject

of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect.

(xxvii)     Title

to Property. The Transaction Entities and their subsidiaries have good and marketable title to, or leasehold interest under a lease

in, all real property owned or leased by them (each, a “Property”, and collectively, the “Properties”),

in each case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except

such as (A) are described in the Registration Statement, the General Disclosure Package and the Prospectus or (B) do not, singly

or in the aggregate, materially affect the value of such Properties taken as a whole and do not interfere with the use made and proposed

to be made of such Properties taken as a whole by the Transaction Entities or any of their subsidiaries. Except as disclosed in the Registration

Statement, the General Disclosure Package and the Prospectus, (A) the Transaction Entities have no knowledge that any Property fails

to comply with all applicable codes, laws and regulations (including, without limitation, building and zoning codes, laws and regulations

and laws relating to access to such Property), except for such failures to comply that would not, singly or in the aggregate, result in

a Material Adverse Effect and (B) no mortgage or deed of trust encumbering any Property is convertible into ownership interests in

a Transaction Entity or any of its subsidiaries.

(xxviii)     Possession

of Intellectual Property. The Transaction Entities and their subsidiaries own or possess, or can acquire on reasonable terms, adequate

patents, patent rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary

or confidential information, systems or procedures), trademarks, service marks, trade names or other intellectual property (collectively,

“Intellectual Property”) necessary to carry on the business now operated by them, and neither of the Transaction Entities

nor any of their subsidiaries has received any notice or is otherwise aware of any infringement of or conflict with asserted rights of

others with respect to any Intellectual Property or of any facts or circumstances which would render any Intellectual Property invalid

or inadequate to protect the interests of the Transaction Entities or any of their subsidiaries therein, and which infringement or conflict

(if the subject of any unfavorable decision, ruling or finding) or invalidity or inadequacy, singly or in the aggregate, would result

in a Material Adverse Effect.

(xxix)       Environmental

Laws. Except as described in the Registration Statement, the General Disclosure Package and the Prospectus or would not, singly or

in the aggregate, result in a Material Adverse Effect, (A) none of the Transaction Entities, any of their subsidiaries or any of

their respective Properties is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy

or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent,

decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air,

surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating

to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum

or petroleum products, asbestos-containing materials or mold (collectively, “Hazardous Materials”) or to the manufacture,

processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental

Laws”), (B) the Transaction Entities, their subsidiaries and the Properties have all permits, authorizations and approvals

required under any applicable Environmental Laws and are each in compliance with their requirements, (C) there are no pending or

threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or

violation, investigations or proceedings relating to any Environmental Law against the Transaction Entities, any of their subsidiaries

or any of the Properties and (D) there are no events or circumstances that would reasonably be expected to form the basis of an order

for clean-up or remediation, or an action, suit or proceeding by any private party or Governmental Entity against or affecting the Transaction

Entities, any of their subsidiaries or any of the Properties relating to Hazardous Materials or any Environmental Laws.

(xxx)        Investment

Company Act. Neither of the Transaction Entities is required to be registered, nor, upon consummation of the transactions contemplated

herein and in the Registration Statement, the General Disclosure Package and the Prospectus (including the sale of the Securities and

the use of proceeds therefrom), will be required to be registered as an “investment company”, under the Investment Company

Act of 1940, as amended (the “1940 Act”).

(xxxi)       Pending

Proceedings and Examinations. The Registration Statement is not the subject of a pending proceeding or examination under Section 8(d) or

8(e) of the 1933 Act, and the Company is not the subject of a pending proceeding under Section 8A of the 1933 Act in connection

with the offering of the Securities.

(xxxii)      Internal

Control and Disclosure Controls. The Company and each of its subsidiaries maintain effective internal control over financial reporting

(as defined under Rule 13a-15(f) and 15d-15(f) under the 1934 Act Regulations) and a system of internal accounting controls

sufficient to provide reasonable assurances that (A) transactions are executed in accordance with management’s general or specific

authorization; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and

to maintain accountability for assets; (C) access to assets is permitted only in accordance with management’s general or specific

authorization; (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate

action is taken with respect to any differences; and (E) the interactive data in eXtensible Business Reporting Language included

in the Registration Statement, the General Disclosure Package and the Prospectus fairly presents the information called for in all material

respects and is prepared in accordance with the Commission's rules and guidelines applicable thereto. Since the end of the Company’s

most recent audited fiscal year, there has been (1) no material weakness in the Company’s internal control over financial reporting

(whether or not remediated) and (2) no change in the Company’s internal control over financial reporting that has materially

affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

The Company and each of its subsidiaries

maintain an effective system of disclosure controls and procedures (as defined in Rule 13a-15 and Rule 15d-15 under the 1934

Act Regulations) that are designed to ensure that information required to be disclosed by the Company in the reports that it files or

submits under the 1934 Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s

rules and forms, and is accumulated and communicated to the Company’s management, including its principal executive officer

or officers and principal financial officer or officers, as appropriate, to allow timely decisions regarding disclosure.

(xxxiii)     Compliance

with the Sarbanes-Oxley Act. There is and has been no failure on the part of the Company or any of the Company’s directors or

officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the

rules and regulations promulgated in connection therewith (the “Sarbanes-Oxley Act”), including Section 402

related to loans and Sections 302 and 906 related to certifications.

(xxxiv)     Payment

of Taxes. Except, in each case, as would not result, singly or in the aggregate, in a Material Adverse Effect, all U.S. federal, state,

local and non-U.S. income tax returns of the Transaction Entities and their subsidiaries required by law to be filed have been filed and

all taxes shown by such returns or otherwise assessed, which are due and payable, have been paid, except assessments against which appeals

have been or will be promptly taken and as to which adequate reserves have been provided. The charges, accruals and reserves on the books

of the Company in respect of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments

or re-assessments for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not

result, singly or in the aggregate, in a Material Adverse Effect.

(xxxv)      Business

Insurance. The Transaction Entities and their subsidiaries carry or are entitled to the benefits of insurance, with financially sound

and reputable insurers, in such amounts and covering such risks as is generally maintained by companies of established repute engaged

in the same or similar business, and all such insurance is in full force and effect. Neither of the Transaction Entities has any reason

to believe that it or any of their respective subsidiaries will not be able (A) to renew, if desired, its existing insurance coverage

as and when such policies expire or (B) to obtain comparable coverage from similar institutions as may be necessary or appropriate

to conduct its business as now conducted and at a cost that would not result in a Material Adverse Effect. Neither of the Transaction

Entities nor any of their subsidiaries has been denied any insurance coverage which it has sought or for which it has applied.

(xxxvi)     Foreign

Corrupt Practices Act. None of the Transaction Entities, any of their subsidiaries or, to the knowledge of either of the Transaction

Entities, any director, officer, agent, employee, affiliate or other person acting on behalf of either of the Transaction Entities or

any of their subsidiaries is aware of or has taken any action, directly or indirectly, that would result in (a) a violation by such

persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”),

including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance

of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization

of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political

party or official thereof or any candidate for foreign political office, in contravention of the FCPA or (b) an offense under the

Bribery Act of 2010 of the United Kingdom (the “UK Bribery Act”), or any other applicable anti-bribery or anti-corruption

laws. Each of the Transaction Entities and their subsidiaries and, to the knowledge of each of the Transaction Entities, their affiliates

have conducted their businesses in compliance with the FCPA, the UK Bribery Act and other applicable anti-bribery or anti-corruption laws

and have instituted and maintain and enforce policies and procedures designed to ensure, and which are reasonably expected to continue

to ensure, continued compliance therewith.

(xxxvii)    Money

Laundering Laws. The operations of each of the Transaction Entities and their subsidiaries are in compliance with applicable financial

recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering

statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,

issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”). No action,

suit or proceeding by or before any Governmental Entity involving the Transaction Entities or any of their subsidiaries with respect to

the Money Laundering Laws is pending or, to the knowledge of either of the Transaction Entities, threatened.

(xxxviii)   OFAC.

None of the Transaction Entities, any of their subsidiaries or, to the knowledge of either of the Transaction Entities, any director,

officer, agent, employee, affiliate or other person acting on behalf of either of the Transaction Entities or any of their subsidiaries

is an individual or entity (“Person”) currently the subject of any sanctions administered or enforced by the United

States Government, including, without limitation, the U.S. Department of the Treasury’s Office of Foreign Assets Control, the United

Nations Security Council, the European Union, His Majesty’s Treasury or other relevant sanctions authority (collectively, “Sanctions”),

nor are the Transaction Entities or any of their subsidiaries located, organized or resident in a country or territory that is the subject

of Sanctions (each, a “Sanctioned Country”); and the Company will not directly or indirectly use the proceeds of the

sale of the Securities, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other

Person (i) to fund or facilitate any activities of or business with any Person, or in any country or territory, that, at the time

of such funding or facilitation, is the subject of Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned

Country or (iii) in any other manner that will result in a violation by any Person (including any Person participating in the transaction,

whether as underwriter, advisor, investor or otherwise) of Sanctions. Since April 24, 2019, the Transaction Entities and their subsidiaries

have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with any Person that at the time of the

dealing or transaction is or was the subject of Sanctions or with any Sanctioned Country.

(xxxix)     Absence

of Manipulation. Neither of the Transaction Entities nor any subsidiary or other affiliate of either of the Transaction Entities has

taken nor will the Transaction Entities nor any of their subsidiaries or other affiliates take, directly or indirectly, any action which

is designed to cause or result in, or which has constituted or which would reasonably be expected to cause or result in, the stabilization

or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities or to result in a violation

of Regulation M under the 1934 Act.

(xl)           Lending

Relationship. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, neither

of the Transaction Entities nor any of their subsidiaries has any material lending or other relationship with any bank or lending

affiliate of any Underwriter.

(xli)         Statistical

and Market-Related Data. Any statistical and market-related data included in the Registration Statement, the General Disclosure Package

or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate

in all material respects and, to the extent required, the Company has obtained the written consent to the use of such data from such sources.

(xlii)        No

Covered Foreign Person. Neither of the Transaction Entities nor any of their subsidiaries is a “covered foreign person,”

as that term is defined in 31 C.F.R. § 850.209. The consummation of the transactions contemplated by this Agreement and described

in the Registration Statement, the General Disclosure Package and the Prospectus will not result in the establishment of a covered foreign

person or the engagement by a “person of a country of concern,” as defined in 31 C.F.R. § 850.221, in a covered activity,

as that term is defined in 31 C.F.R. § 850.208. Neither of the Transaction Entities nor any of their subsidiaries currently engage,

or have plans to engage, directly or indirectly, in a covered activity

(xliii)       Listing.

The Securities have been approved for listing on the New York Stock Exchange, subject to official notice of issuance.

(xliv)       No

Rating. Neither of the Transaction Entities nor any of their subsidiaries has any debt securities or preferred stock that are rated

by any “nationally recognized statistical rating organization” (as defined in Section 3(a)(62) of the 1934 Act).

(xlv)        Cybersecurity.

There has been no security breach or incident, unauthorized access or disclosure, or other compromise of or relating to the Transaction

Entities’ or their respective subsidiaries’ information technology and computer systems, networks, hardware, software, data

and databases (including the data and information of their respective customers, employees, suppliers, vendors and any third party data

maintained, processed or stored by the Transaction Entities and their respective subsidiaries, and any such data processed or stored by

third parties on behalf of the Transaction Entities and their respective subsidiaries), equipment or technology (collectively, “IT

Systems and Data”), except for any such security breach or incident, unauthorized access or disclosure, or other compromise

of or relating to the Transaction Entities’ or their respective subsidiaries’ IT Systems and Data that would not result, singly

or in the aggregate, in a Material Adverse Effect. Neither the Transaction Entities nor their subsidiaries have been notified of, and

each of them have no knowledge of any event or condition that could result in, any material security breach or incident, unauthorized

access or disclosure or other compromise to their IT Systems and Data. The Transaction Entities and their respective subsidiaries have

implemented appropriate controls, policies, procedures, and technological safeguards to maintain and protect the integrity, continuous

operation, redundancy and security of their IT Systems and Data reasonably consistent with industry standards and practices, or as required

by applicable regulatory standards, except where the failure to do so would not result, singly or in the aggregate, in a Material Adverse

Effect. The Transaction Entities and their respective subsidiaries are presently in material compliance with all applicable laws or statutes

and all judgments, orders, rules and regulations of any Governmental Entity, internal policies and contractual obligations relating

to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation

or modification.

(b)            Representations

and Warranties by the Manager. The Manager represents and warrants to each Underwriter as of the date hereof, the Applicable Time,

the Closing Time and each Date of Delivery, if any, and agrees with each Underwriter, as follows:

(i)            Certain

Information. The information provided by the Manager set forth under the headings “Prospectus Summary—Our Manager,”

“Prospectus Summary—Potential Conflicts of Interest,” “Risk Factors—Risks Related to Our Relationship with

Our Manager and Healthpeak” and “Our Manager and the Management Agreement” in the Registration Statement, the General

Disclosure Package and the Prospectus is true and correct in all material respects.

(ii)           Testing-the-Waters

Materials. The Manager (A) has not engaged in any Testing-the-Waters Communication, (B) has not authorized anyone other

than the Representatives to engage in Testing-the-Waters Communications and (C) has not distributed any Written Testing-the-Waters

Communications.

(iii)          No

Material Adverse Change. Since the respective dates as of which information is given in the Registration Statement, the General Disclosure

Package and the Prospectus, except as otherwise stated therein or contemplated thereby there has been no material adverse change, (A) in

the condition, financial or otherwise, or in the earnings, business affairs, management, business prospects or properties (taken as a

whole) of the Manager and its subsidiaries considered as one enterprise, whether or not arising in the ordinary course of business and

(B) in the ability of the Manager to perform its obligations under the Management Agreement (collectively, a “Manager Material

Adverse Effect”).

(iv)          Good

Standing of the Manager. The Manager has been duly formed and is validly existing as a limited liability company in good standing

under the laws of the State of Delaware with limited liability company power and authority to own, lease and operate its properties and

to conduct its business as described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into

and perform its obligations under this Agreement and the Management Agreement. The Manager is duly qualified as a foreign limited liability

company to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of

the ownership or leasing of property or the conduct of business, except where the failure to so qualify and be in good standing would

not have a Manager Material Adverse Effect. The Manager is in substantial compliance with all laws, ordinances and regulations of each

state in which it owns properties that are material to the properties and business of the Manager and its subsidiaries considered as one

enterprise in such state.

(v)           Authorization

of Underwriting Agreement. This Agreement has been duly authorized, executed and delivered by the Manager with respect to the Manager.

(vi)          Management

Agreement. The Management Agreement has been duly authorized, executed and delivered by the Manager and is a valid and legally binding

agreement of the Manager, enforceable against the Manager in accordance with its terms, except to the extent that such enforceability

may be limited by applicable bankruptcy, insolvency, reorganization or other similar laws relating to or affecting creditors’ rights

and general principles of equity.

(vii)         Absence

of Violations, Defaults and Conflicts. The Manager is not (i) in violation of its operating agreement or other organizational

document or (ii) in default in the performance or observance of any obligation, agreement, covenant or condition contained in any

contract, indenture, mortgage, loan agreement, note, lease or other instrument to which the Manager is a party or by which the Manager

may be bound or to which any of the properties or assets of the Manager is subject and in which the violation or default might result

in a Manager Material Adverse Effect. The execution, delivery and performance of this Agreement and the Management Agreement by the Manager

and the consummation of the transactions contemplated herein and therein and in the Registration Statement, the General Disclosure Package

and the Prospectus and compliance by the Manager with its obligations hereunder and thereunder have been duly authorized by all necessary

action and will not conflict with or constitute a breach of, or default under, or result in the creation or imposition of any lien, charge

or encumbrance upon any properties or assets of the Manager pursuant to, any contract, indenture, mortgage, loan agreement, note, lease

or other instrument to which the Manager is a party or by which the Manager may be bound or to which any of the properties or assets of

the Manager is subject, nor will such action result in any violation of the provisions of (i) the certificate of formation, limited

liability company agreement or other comparable governing document of the Manager or (ii) any law, statute, rule, regulation, judgment,

order, writ or decree of any court or governmental agency or body, domestic or foreign having jurisdiction over the Manager (a “Manager

Governmental Entity”).

(viii)        Absence

of Manipulation. The Manager has not taken and will not take, directly or indirectly, any action which is designed to cause or result

in, or which has constituted or which would reasonably be expected to cause or result in, the stabilization or manipulation of the price

of any security of the Company to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under the

1934 Act.

(ix)          Absence

of Further Requirements. No authorization, approval, consent, order or decree of any Manager Governmental Entity is required for the

consummation by the Manager of the transactions contemplated by this Agreement or the Management Agreement.

(x)           Absence

of Proceedings. Except as disclosed in the Registration Statement, the General Disclosure Package or the Prospectus, there is no action,

suit or proceeding before or by any Manager Governmental Entity now pending, or, to the knowledge of the Manager, threatened against or

affecting the Manager, which would result in any Manager Material Adverse Effect, or which would materially and adversely affect the Manager’s

properties or assets, taken as a whole, or which would materially and adversely affect the consummation of this Agreement or the Management

Agreement or the performance by the Manager of its obligations hereunder or thereunder. All pending legal or governmental proceedings

to which the Manager is a party or of which any of its properties or assets is the subject which are not described in the Registration

Statement, the General Disclosure Package or the Prospectus, including ordinary routine litigation incidental to the business, are, considered

in the aggregate, not material to the Manager.

(xi)          Employment;

Noncompetition; Nondisclosure. The Manager has not been notified that any executive officer or key employee of Healthpeak or the Manager

plans to terminate his, her or their employment with his, her or their current employer. Neither the Manager nor, to the knowledge of

the Manager, any executive officer or key employee of Healthpeak or the Manager is subject to any noncompete, nondisclosure, confidentiality,

employment, consulting or similar agreement that would be violated by the present or proposed business activities of the Transaction Entities

or the Manager as described in the Registration Statement, the General Disclosure Package and the Prospectus, except for such violations

that would not, singly or in the aggregate, result in a Material Adverse Effect.

(xii)         Foreign

Corrupt Practices Act. None of the Manager, any of its subsidiaries or, to the knowledge of the Manager, any director, officer, agent,

employee, affiliate or other person acting on behalf of the Manager or any of its subsidiaries is aware of or has taken any action, directly

or indirectly, that would result in (a) a violation by such persons of the FCPA, including, without limitation, making use of the

mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization

of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign

official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign

political office, in contravention of the FCPA or (b) an offense under the UK Bribery Act or any other applicable anti-bribery or

anti-corruption laws. The Manager and its subsidiaries and, to the knowledge of the Manager, its other affiliates have conducted their

businesses in compliance with the FCPA, the UK Bribery Act and other applicable anti-bribery or anti-corruption laws and have instituted

and maintain and enforce policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued

compliance therewith.

(xiii)        Money-Laundering

Laws. The operations of the Manager and its subsidiaries are in compliance with applicable financial recordkeeping and reporting requirements

of the Money Laundering Laws. No action, suit or proceeding by or before any Manager Governmental Entity involving the Manager or any

of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Manager, threatened.

(xiv)        OFAC.

None of the Manager, any of its subsidiaries or, to the knowledge of the Manager, any director, officer, agent, employee, affiliate or

other person acting on behalf of the Manager or any of its subsidiaries is currently the subject of any Sanctions, nor is the Manager

or any of its subsidiaries located, organized or resident in a country or territory that is the subject of Sanctions. Since April 24,

2019, the Manager and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions

with any Person that at the time of the dealing or transaction is or was the subject of Sanctions or with any Sanctioned Country.

(xv)         Possession

of Licenses and Permits. The Manager possesses such Governmental Licenses issued by the appropriate governmental agencies or bodies,

domestic or foreign, necessary for the Manager to perform its obligations under the Management Agreement. The Manager is in compliance

with the terms and conditions of all Governmental Licenses under applicable law, except where the failure so to comply would not, singly

or in the aggregate, affect its ability to perform its obligations under the Management Agreement. All of the Governmental Licenses are

valid and in full force and effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses

to be in full force and effect would not, singly or in the aggregate, affect its ability to perform its obligations under the Management

Agreement. The Manager has not received any notice of proceedings relating to the revocation or modification of any Governmental Licenses

which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would affect its ability to perform its

obligations under the Management Agreement.

(xvi)        Internal

Control. The Manager maintains an effective system of internal controls sufficient to provide reasonable assurance that (A) transactions

that may be effectuated by it on behalf of the Transaction Entities pursuant to its obligations under the Management Agreement will be

executed in accordance with management’s general or specific authorization and (B) access to the Transaction Entities’

assets is permitted only in accordance with management’s general or specific authorization.

(xvii)       Cybersecurity.

There has been no security breach or incident, unauthorized access or disclosure, or other compromise of or relating to the Manager’s

or its subsidiaries’ IT Systems and Data, except for any such security breach or incident, unauthorized access or disclosure, or

other compromise of or relating to the Manager’s or its subsidiaries’ IT Systems and Data that would not result, singly or

in the aggregate, in a Manager Material Adverse Effect. Neither the Manager nor its subsidiaries have been notified of, and each of them

have no knowledge of any event or condition that could result in, any material security breach or incident, unauthorized access or disclosure

or other compromise to their IT Systems and Data. The Manager and its subsidiaries have implemented appropriate controls, policies, procedures,

and technological safeguards to maintain and protect the integrity, continuous operation, redundancy and security of their IT Systems

and Data reasonably consistent with industry standards and practices, or as required by applicable regulatory standards, except where

the failure to do so would not result, singly or in the aggregate, in a Manager Material Adverse Effect. The Manager and its subsidiaries

are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any

Manager Governmental Entity, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data

and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification.

Certificates. Any certificate signed by any officer or other representative of either of the Transaction Entities delivered to the

Representatives or to counsel for the Underwriters shall be deemed a representation and warranty by both Transaction Entities to each

Underwriter as to the matters covered thereby; and any certificate signed by any officer or other representative of the Manager as such

and delivered to the Representatives or to counsel for the Underwriters pursuant to the terms of this Agreement shall be deemed a representation

and warranty by the Manager to each Underwriter as to the matters covered thereby.

Section 2.                Sale

and Delivery to Underwriters; Closing.

(a)            Initial

Securities. On the basis of the representations and warranties herein contained and subject to the terms and conditions herein set

forth, the Company agrees to sell to each Underwriter, severally and not jointly, and each Underwriter, severally and not jointly, agrees

to purchase from the Company, at the price per share set forth in Schedule A hereto, that number of Initial Securities opposite such Underwriter’s

name on Schedule A hereto, plus any additional number of Initial Securities which such Underwriter may become obligated to purchase pursuant

to the provisions of Section 11 hereof, subject, in each case, to such adjustments among the Underwriters as the Representatives

in their sole discretion shall make to eliminate any sales or purchases of fractional shares.

(b)            Option

Securities. In addition, on the basis of the representations and warranties herein contained and subject to the terms and conditions

herein set forth, the Company hereby grants an option to the Underwriters, severally and not jointly, to purchase up to an additional

3,750,000 Option Securities, at the price per share set forth in Schedule A, less an amount per share equal to any dividends or distributions

declared by the Company and payable on the Initial Securities but not payable on the Option Securities. The option hereby granted may

be exercised for 30 days after the date hereof and may be exercised in whole or in part at any time from time to time upon notice by the

Representatives to the Company setting forth the number of Option Securities as to which the several Underwriters are then exercising

the option and the time and date of payment and delivery for such Option Securities. Any such time and date of delivery (a “Date

of Delivery”) shall be determined by the Representatives, but shall not be later than seven full business days after the exercise

of said option, nor in any event prior to the Closing Time. If the option is exercised as to all or any portion of the Option Securities,

each of the Underwriters, acting severally and not jointly, will purchase that proportion of the total number of Option Securities then

being purchased which the number of Initial Securities set forth in Schedule A opposite the name of such Underwriter bears to the total

number of Initial Securities, subject, in each case, to such adjustments as the Representatives in their sole discretion shall make to

eliminate any sales or purchases of fractional shares.

Payment of the purchase price for, and delivery of certificates for or book-entry credits representing, the Initial Securities shall be

made at the offices of Sidley Austin LLP, 787 7th Ave, New York, New York 10019, or at such other place as shall be agreed upon by the

Representatives and the Company, at 9:00 A.M. (New York City time) on the first (second, if the pricing occurs after 4:30 P.M. (New

York City time) on any given day) business day after the date hereof (unless postponed in accordance with the provisions of Section 11),

or such other time not later than ten business days after such date as shall be agreed upon by the Representatives and the Company (such

time and date of payment and delivery being herein called “Closing Time”).

In addition, in the event that any or all of the

Option Securities are purchased by the Underwriters, payment of the purchase price for, and delivery of certificates for or book-entry

credits representing, such Option Securities shall be made at the above-mentioned offices, or at such other place as shall be agreed upon

by the Representatives and the Company, on each Date of Delivery as specified in the notice from the Representatives to the Company.

Payment shall be made to the Company by wire transfer

of immediately available funds to a bank account designated by the Company against delivery to the Representatives for the respective

accounts of the Underwriters of certificates for or book-entry credits representing the Securities to be purchased by them. It is understood

that each Underwriter has authorized the Representatives, for its account, to accept delivery of, receipt for, and make payment of the

purchase price for, the Initial Securities and the Option Securities, if any, which it has agreed to purchase. Each of BofA, J.P. Morgan,

RBC and Wells Fargo, individually and not as a representative of the Underwriters, may (but shall not be obligated to) make payment of

the purchase price for the Initial Securities or the Option Securities, if any, to be purchased by any Underwriter whose funds have not

been received by the Closing Time or the relevant Date of Delivery, as the case may be, but such payment shall not relieve such Underwriter

from its obligations hereunder.

Section 3.                Covenants

of the Transaction Entities. Each of the Transaction Entities, jointly and severally, covenants with each Underwriter as follows:

(a)            Compliance

with Securities Regulations and Commission Requests. The Company, subject to Section 3(e), will comply with the requirements

of Rule 430A, and will notify the Representatives promptly, and confirm the notice in writing, (i) when any post-effective amendment

to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed, (ii) of

the receipt of any comments or inquiries from the Commission relating to the Registration Statement, any preliminary prospectus or the

Prospectus, (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement

to the Prospectus or for additional information, (iv) of the issuance by the Commission of any stop order suspending the effectiveness

of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any preliminary prospectus

or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation

or threatening of any proceedings for any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the

1933 Act concerning the Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of

the 1933 Act in connection with the offering of the Securities. The Company will effect all filings required under Rule 424(b), in

the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such

steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was

received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company will make

every reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain

the lifting thereof at the earliest possible moment.

(b)            Issuer

Free Writing Prospectuses. Each of the Transaction Entities agrees that, unless it obtains the prior written consent of the Representatives,

it will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise

constitute a “free writing prospectus,” or a portion thereof, required to be filed by the Company with the Commission or retained

by the Company under Rule 433; provided that the Representatives will be deemed to have consented to the Issuer Free Writing Prospectuses

listed on Schedule B-2 hereto and any “road show that is a written communication” within the meaning of Rule 433(d)(8)(i) that

has been reviewed and approved by the Representatives. Each of the Transaction Entities represents that it has treated or agrees that

it will treat each such free writing prospectus consented to, or deemed consented to, by the Representatives as an “issuer free

writing prospectus,” as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433

with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following

issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing

Prospectus conflicted or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the

Prospectus or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary

in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company

will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus

to eliminate or correct such conflict, untrue statement or omission.

of Registration Statements. The Company has furnished or will deliver to the Representatives and counsel for the Underwriters, without

charge, an electronic copy of the Registration Statement as originally filed and of each amendment thereto (including exhibits filed therewith).

(d)            Delivery

of Prospectuses. The Company has delivered to each Underwriter, without charge, as many copies of each preliminary prospectus as such

Underwriter reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the 1933 Act. The

Company will furnish to each Underwriter, without charge, during the period when a prospectus relating to the Securities is (or, but for

the exception afforded by Rule 172 (as defined below), would be) required to be delivered under the 1933 Act, such number of copies

of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments or supplements

thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant

to EDGAR, except to the extent permitted by Regulation S-T.

(e)            Continued

Compliance with Securities Laws. The Company will comply with the 1933 Act and the 1933 Act Regulations so as to permit the completion

of the distribution of the Securities as contemplated in this Agreement and in the Registration Statement, the General Disclosure Package

and the Prospectus. If at any time when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172

of the 1933 Act Regulations (“Rule 172”), would be) required by the 1933 Act to be delivered in connection with

sales of the Securities, any event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel

for the Underwriters or for the Company, to (i) amend the Registration Statement in order that the Registration Statement will not

include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the

statements therein not misleading, (ii) amend or supplement the General Disclosure Package or the Prospectus in order that the General

Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state a

material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading

at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or supplement the General Disclosure

Package or the Prospectus, as the case may be, in order to comply with the requirements of the 1933 Act or the 1933 Act Regulations, the

Company will promptly (A) give the Representatives notice of such event, (B) prepare any amendment or supplement as may be necessary

to correct such statement or omission or to make the Registration Statement, the General Disclosure Package or the Prospectus comply with

such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish the Representatives with copies of any

such amendment or supplement and (C) file with the Commission any such amendment or supplement; provided that the Company shall not

file or use any such amendment or supplement to which the Representatives or counsel for the Underwriters shall reasonably object. The

Company will furnish to the Underwriters such number of copies of such amendment or supplement as the Underwriters may reasonably request.

The Company has given the Representatives notice of any filings made pursuant to the 1934 Act or 1934 Act Regulations within 48 hours

prior to the Applicable Time; the Company will give the Representatives notice of its intention to make any such filing from the Applicable

Time to the Closing Time and will furnish the Representatives with copies of any such documents a reasonable amount of time prior to such

proposed filing, as the case may be, and will not file or use any such document to which the Representatives or counsel for the Underwriters

shall reasonably object.

(f)            Blue

Sky Qualifications. The Company will endeavor, in cooperation with the Underwriters, to qualify the Securities for offering and sale

under the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Representatives may reasonably

designate and to maintain such qualifications in effect so long as required to complete the distribution of the Securities; provided,

however, that the Company shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation

or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing

business in any jurisdiction in which it is not otherwise so subject.

(g)            Rule 158.

The Company will timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available to its securityholders

an earnings statement for the purposes of, and to provide to the Underwriters the benefits contemplated by, the last paragraph of Section 11(a) of

the 1933 Act.

(h)            Use

of Proceeds. The Company will use the net proceeds received by it from the sale of the Securities in the manner specified in the Registration

Statement, the General Disclosure Package and the Prospectus under “Use of Proceeds.”

(i)            Listing.

The Company will use its best efforts to effect and maintain the listing of the Securities on the New York Stock Exchange.

(j)            Reporting

Requirements. The Company, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by

Rule 172, would be) required to be delivered under the 1933 Act, will file all documents required to be filed with the Commission

pursuant to the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations.

(k)            Restriction

on Sale of Securities. During a period of 90 days from the date of this Agreement (the “Lock-Up Period”), neither

of the Transaction Entities will, without the prior written consent of BofA and J.P. Morgan, directly or indirectly (i) offer, pledge,

sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant

to purchase or otherwise transfer or dispose of any shares of Class A-1 Common Stock or any securities convertible into or exercisable

or exchangeable for Class A-1 Common Stock (including, without limitation, LLC Interests) or file or confidentially submit any registration

statement under the 1933 Act relating to any shares of Class A-1 Common Stock or any securities convertible into or exercisable or

exchangeable for Class A-1 Common Stock (including, without limitation, LLC Interests), or (ii) enter into any swap or other

agreement or transaction that transfers, in whole or in part, directly or indirectly, the economic consequences of ownership of Class A-1

Common Stock, whether any such swap, agreement, or other transaction described in clause (i) or (ii) above is to be settled

by delivery of Class A-1 Common Stock, other securities, in cash or otherwise, or publicly announce the intention to do any of the

foregoing described in clause (i) or (ii), except for (A) the Securities to be sold hereunder, (B) shares of Common Stock

or LLC Interests issued or options to purchase shares of Common Stock or LLC Interests granted pursuant to, or registration statements

on Form S-8 filed to register shares of Class A-1 Common Stock that are issuable pursuant to, existing employee benefit plans

of the Company referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (C) non-managing member

units exchangeable for any shares of Class A-1 Common Stock issued by subsidiaries of the Company in connection with the acquisition

of properties or interests therein (provided that (x) such units referred to in this clause (C) are not exchangeable for Class A-1

Common Stock for at least one year from the date of issuance thereof and the Company does not cause or permit (by waiver or otherwise)

the exchange of such units for Class A-1 Common Stock during such one year period, (y) issuances pursuant to this clause (C) shall

not in the aggregate exceed 5% of the total number of shares of Class A-1 Common Stock issued and outstanding immediately following

the completion of the transactions contemplated by this Agreement (assuming full conversion, exchange or exercise of all outstanding securities

convertible into or exercisable or exchangeable for shares of Class A-1 Common Stock (including LLC Interests)) and (z) the

recipient of any such units or securities convertible into or exercisable or exchangeable for shares of Class A-1 Common Stock shall

be required to execute a Lock-up Agreement in substantially the form attached as Exhibit C hereto for the duration of the Lock-Up

Period), (D) any shares of Common Stock issued by the Company upon the exercise of an option or warrant or the conversion of a security

outstanding on the date hereof and referred to in the Registration Statement, the General Disclosure Package and the Prospectus, (E) shares

of Class A-1 Common Stock issuable, and shares of Class A-2 Common Stock cancellable, upon the redemption or exchange of non-managing

member units of subsidiaries of the Company, including the Operating Company, outstanding on the date of this Agreement and referred to

in the Registration Statement, the General Disclosure Package and the Prospectus, (F) shares of Class A-1 Common Stock issued

under a registration statement or pursuant to an exemption from registration in connection with future business combinations or acquisitions;

provided that (x) such issuance does not exceed 5% of the total number of shares of Class A-1 Common Stock issued and outstanding

immediately following the completion of the transactions contemplated by this Agreement (assuming full conversion, exchange or exercise

of all outstanding securities convertible into or exercisable or exchangeable for shares of Class A-1 Common Stock (including LLC

Interests)) and (y) the recipient of any such Class A-1 Common Stock or securities convertible into or exercisable or exchangeable

for shares of Class A-1 Common Stock during the Lock-Up Period shall be required to execute a Lock-up Agreement in substantially

the form attached as Exhibit C hereto for the duration of the Lock-Up Period, (G) shares of Common Stock issued as part of a

distribution by the Company to its stockholders of record as of the record date of such distribution to maintain the qualification of

the Company as a REIT or to avoid the payment of federal or state income or excise taxes or (H) LLC Interests issued to the Company.

(l)            Certification

Regarding Beneficial Owners. The Company will deliver to the Representatives, on the date of execution of this Agreement, a properly

completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation,

and the Company undertakes to provide such additional supporting documentation as the Representatives may reasonably request in connection

with the verification of the foregoing certification.

(m)            Emerging

Growth Company Status. The Company will promptly notify the Representatives if the Company ceases to be an Emerging Growth Company

at any time prior to the later of (i) completion of the distribution of the Securities within the meaning of the 1933 Act and (ii) completion

of the 90-day restricted period referred to in Section 3(k).

(n)            Absence

of Manipulation. Neither of the Transaction Entities nor any subsidiary or other affiliate of the Transaction Entities will take,

directly or indirectly, any action which is designed to cause or result in, or which has constituted or which would reasonably be expected

to cause or result in, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale

of the Securities or to result in a violation of Regulation M under the 1934 Act.

(o)            REIT

Status. The Company will use its reasonable best efforts to meet the requirements for qualification and taxation as a REIT under the

Code for its taxable year ending December 31, 2026, and the Company will use its reasonable best efforts to continue to qualify for

taxation as a REIT under the Code unless the Board of Directors of the Company determines that it is no longer in the best interests of

the Company to qualify or to be so qualified.

Section 4.                Covenants

of the Manager.

(a)            Accurate

Disclosure. The Manager covenants with each Underwriter and with the Company that, if at any time during the period when a prospectus

relating to the Securities is required (or, but for the exception afforded by Rule 172 under the 1933 Act, would be required) to

be delivered under the 1933 Act, it shall notify the Representatives and the Company of the occurrence of any material events respecting

the Manager’s activities, affairs, operations or condition, financial or otherwise, and the Manager will forthwith supply such information

to the Company as shall be necessary in the opinion of counsel to the Transaction Entities and the Underwriters for the Company to prepare

any necessary amendment or supplement to the Registration Statement, the General Disclosure Package and the Prospectus so that, as so

amended or supplemented, the same will not include any untrue statement of a material fact or omit to state a material fact necessary

in order to make the statements therein, in the light of the circumstances under which they were made (in the case of the General Disclosure

Package and the Prospectus), not misleading.

(b)            Absence

of Manipulation. The Manager will not take, directly or indirectly, any action which is designed to cause or result in, or which has

constituted or which would reasonably be expected to cause or result in, the stabilization or manipulation of the price of any security

of the Company to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under the 1934 Act.

Section 5.                Payment

of Expenses.

(a)            Expenses.

Each of the Transaction Entities, jointly and severally, will pay or cause to be paid all expenses incident to the performance of their

obligations under this Agreement, including (i) the preparation, printing and filing of the Registration Statement (including financial

statements and exhibits thereto) as originally filed and of each amendment thereto, (ii) the preparation, printing and delivery to

the Underwriters of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments or

supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Underwriters to investors, (iii) the

preparation, issuance and delivery of the certificates for the Securities to the Underwriters, including any stock or other transfer taxes

and any stamp or other duties payable upon the sale, issuance or delivery of the Securities to the Underwriters, (iv) the fees and

disbursements of the Transaction Entities’ counsel, accountants and other advisors, (v) the qualification of the Securities

under securities laws in accordance with the provisions of Section 3(f) hereof, including filing fees and the reasonable fees

and disbursements of counsel for the Underwriters in connection therewith and in connection with the preparation of the Blue Sky Survey

and any supplement thereto (in an amount not to exceed $10,000), (vi) the fees and expenses of any transfer agent or registrar for

the Securities, (vii) the costs and expenses of the Company relating to investor presentations on any “road show” undertaken

in connection with the marketing of the Securities, including without limitation, expenses associated with the production of road show

slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations, travel and lodging expenses

of the officers and other representatives of the Transaction Entities and any such consultants, and 50% of the cost of any aircraft and

other transportation chartered in connection with the road show (the remaining 50% of such cost to be paid by the Underwriters), (viii) the

filing fees incident to, and the reasonable and documented fees and disbursements of counsel to the Underwriters in connection with, the

review by FINRA of the terms of the sale of the Securities (in an amount not to exceed $30,000), (ix) the fees and expenses incurred

in connection with the listing of the Securities on the New York Stock Exchange and (x) the costs and expenses (including, without

limitation, any damages or other amounts payable in connection with legal or contractual liability) associated with the reforming of any

contracts for sale of the Securities made by the Underwriters caused by a breach of the representation contained in the second sentence

of Section 1(a)(ii).

(b)            Termination

of Agreement. If this Agreement is terminated by the Representatives in accordance with the provisions of Section 6, Section 10(a)(i) or

(iii) or Section 11 hereof, the Company shall reimburse the Underwriters for all of their out-of-pocket expenses, including

the reasonable fees and disbursements of counsel for the Underwriters.

Section 6.                Conditions

of the Underwriters’ Obligations. The obligations of the several Underwriters hereunder are subject to the accuracy of the representations

and warranties of the Transaction Entities and the Manager contained herein or in certificates of any officer or other representative

of the Transaction Entities or any of its subsidiaries or the Manager delivered pursuant to the provisions hereof, to the performance

by the Transaction Entities and the Manager of their respective covenants and other obligations hereunder, and to the following further

conditions:

(a)            Effectiveness

of Registration Statement; Rule 430A Information. The Registration Statement, including any Rule 462(b) Registration

Statement, has become effective and, at the Closing Time, no stop order suspending the effectiveness of the Registration Statement or

any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of any preliminary

prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the

Company’s knowledge, contemplated; and the Company has complied with each request (if any) from the Commission for additional information.

A prospectus containing the Rule 430A Information shall have been filed with the Commission in the manner and within the time frame

required by Rule 424(b) without reliance on Rule 424(b)(8) or a post-effective amendment providing such information

shall have been filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430A.

(b)            Opinions.

At the Closing Time, the Representatives shall have received:

(i)            The

favorable opinions and negative assurance letter, dated the Closing Time, of Latham & Watkins LLP, special corporate and tax

counsel to the Transaction Entities and special corporate counsel to the Manager, in the form and substance reasonably satisfactory to

the Representatives as set forth in Exhibit A hereto. In rendering such opinion, Latham & Watkins LLP may rely upon the

opinion of Ballard Spahr LLP, rendered pursuant to Section 6(b)(ii), as to matters arising under the laws of the State of Maryland.

(ii)           The

favorable opinion, dated the Closing Time, of Ballard Spahr LLP, Maryland counsel for the Transaction Entities, in the form and substance

reasonably satisfactory to the Representatives as set forth in Exhibit B hereto. In rendering its opinion, Ballard Spahr LLP shall

state that each of Sidley Austin LLP, in rendering its opinion pursuant to Section 6(b)(iii) and Latham & Watkins LLP,

in rendering its opinions pursuant to Section 6(b)(i), may rely upon such opinion as to matters arising under the laws of the State

of Maryland.

(iii)          The

favorable opinion (including negative assurance statement), dated the Closing Time, of Sidley Austin LLP, counsel to the Underwriters,

with respect to such matters as the Underwriters may reasonably request. In rendering such opinion, Sidley Austin LLP may rely upon the

opinion of Ballard Spahr LLP, rendered pursuant to Section 6(b)(ii), as to matters arising under the laws of the State of Maryland.

In giving their opinions, Latham & Watkins

LLP, Ballard Spahr LLP and Sidley Austin LLP may rely, to the extent recited therein, (A) as to all matters of fact, upon certificates

and written statements of officers of the Transaction Entities and the Manager, and (B) as to the qualification and good standing

of the Company, the Operating Company and the Manager and each Significant Subsidiary to do business in any state or other jurisdiction,

upon certificates of appropriate government officials.

Certificate. At the Closing Time, there shall not have been, since the date hereof or since the respective dates as of which information

is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition,

financial or otherwise, or in the earnings, business affairs or business prospects of the Transaction Entities and their subsidiaries

considered as one enterprise, whether or not arising in the ordinary course of business, and the Representatives shall have received a

certificate of the President or a Vice President of the Company and of the Chief Financial Officer or Chief Accounting Officer of the

Company, dated the Closing Time, to the effect that (i) there has been no such material adverse change, (ii) the representations

and warranties of the Transaction Entities in Section 1(a) hereof are true and correct with the same force and effect as though

expressly made at and as of the Closing Time, (iii) the Transaction Entities have performed or complied with all agreements and satisfied

all conditions on their part to be performed or satisfied at or prior to the Closing Time and (iv) no stop order suspending the effectiveness

of the Registration Statement under the 1933 Act has been issued, no order preventing or suspending the use of any preliminary prospectus

or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to their knowledge,

contemplated.

(d)            Certificate

of the Manager. At the Closing Time, the Representatives shall have received a certificate of an officer of the Manager, dated the

Closing Time, to the effect that (i) the representations and warranties of the Manager in Section 1(b) hereof are true

and correct with the same force and effect as though expressly made at and as of the Closing Time and (ii) the Manager has performed

or complied with all agreements and satisfied all conditions on its part to be performed or satisfied under this Agreement at or prior

to the Closing Time.

(e)            Accountants’

Comfort Letter. At the time of the execution of this Agreement, the Representatives shall have received from Deloitte & Touche

LLP, in its capacity as auditor of the Company, dated such date, in form and substance satisfactory to the Representatives, containing

statements and information of the type ordinarily included in accountants’ “comfort letters” to underwriters with respect

to financial statements and financial information included in the Registration Statement, the General Disclosure Package and the Prospectus.

(f)            Bring-down

Comfort Letter. At the Closing Time, the Representatives shall have received from Deloitte & Touche LLP, in its capacity

as auditor of the Company, dated the Closing Time, to the effect that they reaffirm the statements made in their letter furnished pursuant

to subsection (e) of this Section, except that the specified date referred to therein shall be a date not more than three business

days prior to the Closing Time.

(g)            Chief

Financial Officer’s Certificate. At the time of execution of this Agreement and at the Closing Time, the Representatives shall

have received a certificate of the Chief Financial Officer of the Company, dated the date hereof and the Closing Time, in form and substance

satisfactory to the Representatives, regarding certain financial and operating information contained in the Registration Statement, the

General Disclosure Package and the Prospectus.

(h)            Approval

of Listing. At the Closing Time, the Securities shall have been approved for listing on the New York Stock Exchange, subject only

to official notice of issuance.

(i)            No

Objection. FINRA has confirmed that it has not raised any objection with respect to the fairness and reasonableness of the underwriting

terms and arrangements relating to the offering of the Securities.

(j)            Additional

Documents. At the Closing Time, and each Date of Delivery, counsel for the Underwriters shall have been furnished with such documents

and opinions as they may reasonably require for the purpose of enabling them to pass upon the sale of the Securities as herein contemplated

and related proceedings, or in order to evidence the accuracy and completeness of any of the representations and warranties, or the fulfillment

of any of the conditions, herein contained.

(k)            Conditions

to Purchase of Option Securities. In the event that the Underwriters exercise their option provided in Section 2(b) hereof

to purchase all or any portion of the Option Securities, the representations and warranties of the Transaction Entities and the Manager

contained herein and the statements in any certificates furnished by the Transaction Entities or any of their respective subsidiaries

or the Manager hereunder shall be true and correct as of each Date of Delivery, and, at the relevant Date of Delivery, the Representatives

shall have received:

(i)            The

favorable opinions and negative assurance letter of Latham & Watkins LLP, special corporate and tax counsel to the Transaction

Entities and special corporate counsel to the Manager, in form and substance satisfactory to counsel for the Underwriters, dated

such Date of Delivery, relating to the Option Securities and otherwise to the same effect as the opinions and negative assurance letter

required by Section 6(b)(i) hereof.

(ii)           The

favorable opinion of Ballard Spahr LLP, Maryland counsel to the Transaction Entities, in form and substance satisfactory to counsel

for the Underwriters, dated such Date of Delivery, relating to the Option Securities and otherwise to the same effect as the opinion required

by Section 6(b)(ii) hereof.

(iii)          The

favorable opinion (including negative assurance statement) of Sidley Austin LLP, counsel to the Underwriters, dated such Date of Delivery,

relating to the Option Securities and otherwise to the same effect as the opinion required by Section 6(b)(iii) hereof.

(iv)          A

certificate of the President or a Vice President of the Company and of the Chief Financial Officer or Chief Accounting Officer of the

Company, dated such Date of Delivery, confirming that the certificate delivered at the Closing Time pursuant to Section 6(c) hereof

remains true and correct as of such Date of Delivery.

(v)           A

certificate of an officer of the Manager, dated such Date of Delivery, confirming that the certificate delivered at the Closing Time pursuant

to Section 6(d) hereof remains true and correct as of such Date of Delivery.

(vi)          A

letter from Deloitte & Touche LLP, in form and substance satisfactory to the Representatives, dated such Date of Delivery,

substantially the same in scope and substance as the letter furnished to the Representatives, pursuant to Section 6(f) hereof

except that the “specified date” in the letters furnished pursuant to this subsection shall be a date not more than three

business days prior to such Date of Delivery.

(vii)         A

certificate of the Chief Financial Officer of the Company, dated such Date of Delivery, confirming that the certificate delivered at the

Closing Time pursuant to Section 6(g) hereof remains true and correct as of such Date of Delivery.

If any condition specified in this Section shall

not have been fulfilled when and as required to be fulfilled, this Agreement, or, in the case of any condition to the purchase of Option

Securities on a Date of Delivery which is after the Closing Time, the obligations of the several Underwriters to purchase the relevant

Option Securities, may be terminated by the Representatives by notifying the Company at any time at or prior to Closing Time or such Date

of Delivery, as the case may be, and such termination shall be without liability of any party to any other party except as provided in

Section 5 hereof. Notwithstanding any such termination, the provisions of Section 1, Section 7, Section 8, Section 9,

Section 13, Section 14, Section 19 and Section 20 shall remain in full force and effect.

Section 7.                Indemnification.

(a)            Indemnification

of the Underwriters. Each of the Transaction Entities, jointly and severally, agree to indemnify and hold harmless each Underwriter,

its affiliates (as such term is defined in Rule 501(b) under the 1933 Act (each, an “Affiliate”)), its directors,

officers and agents, and each person, if any, who controls any Underwriter within the meaning of Section 15 of the 1933 Act or Section 20

of the 1934 Act, as follows:

(i)            against

any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out of any untrue statement or alleged untrue

statement of a material fact contained in the Registration Statement (or any amendment thereto), including the Rule 430A Information,

or any omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein

not misleading or arising out of any untrue statement or alleged untrue statement of a material fact included (A) in any preliminary

prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto),

or (B) in any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing

of the offering of the Securities (“Marketing Materials”), including any roadshow or investor presentations made to

investors by the Company (whether in person or electronically), or the omission or alleged omission in any preliminary prospectus, any

Issuer Free Writing Prospectus, the General Disclosure Package or the Prospectus (or any amendment or supplement thereto) or in any Marketing

Materials of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were

made, not misleading;

(ii)           against

any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the extent of the aggregate amount paid in settlement

of any litigation, or any investigation or proceeding by any governmental agency or body, domestic or foreign, commenced or threatened,

or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided

that (subject to Section 7(d) below) any such settlement is effected with the written consent of the Transaction Entities; and

(iii)          against

any and all expense whatsoever, as incurred (including the fees and disbursements of counsel chosen by the Representatives), reasonably

incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency

or body, domestic or foreign, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any

such alleged untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above;

provided, however,

that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any untrue

statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including

the Rule 430A Information, or the General Disclosure Package or the Prospectus (or any amendment or supplement thereto), in each

case, in reliance upon and in conformity with the Underwriter Information.

(b)            Indemnification

of the Transaction Entities and the Company’s Directors and Officers. Each Underwriter, severally and not jointly, agrees to

indemnify and hold harmless each Transaction Entity, the Company’s directors, each of the Company’s officers who signed the

Registration Statement, and each person, if any, who controls either of the Transaction Entities within the meaning of Section 15

of the 1933 Act or Section 20 of the 1934 Act, against any and all loss, liability, claim, damage and expense described in the indemnity

contained in subsection (a) of this Section, as incurred, but only with respect to untrue statements or omissions, or alleged

untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including the Rule 430A Information,

or the General Disclosure Package or the Prospectus (or any amendment or supplement thereto), in each case in reliance upon and in conformity

with the Underwriter Information.

Against Parties; Notification. Each indemnified party shall give written notice as promptly as reasonably practicable to each indemnifying

party of any action commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying

party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result

thereof and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement.

In the case of parties indemnified pursuant to Section 7(a) above, counsel to the indemnified parties shall be selected by the

Representatives, and, in the case of parties indemnified pursuant to Section 7(b) above, counsel to the indemnified parties

shall be selected by the Transaction Entities. An indemnifying party may participate at its own expense in the defense of any such action;

provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel

to the indemnified party. In no event shall the indemnifying parties be liable for fees and expenses of more than one counsel (in addition

to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar

or related actions in the same jurisdiction arising out of the same general allegations or circumstances. No indemnifying party shall,

without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect

to any litigation, or any investigation or proceeding by any governmental agency or body, domestic or foreign, commenced or threatened,

or any claim whatsoever in respect of which indemnification or contribution could be sought under this Section 7 or Section 8

hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent

(i) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation,

proceeding or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on

behalf of any indemnified party.

(d)            Settlement

without Consent if Failure to Reimburse. If at any time an indemnified party shall have requested an indemnifying party to reimburse

the indemnified party for fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the

nature contemplated by Section 7(a)(ii) effected without its written consent if (i) such settlement is entered into more

than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received

notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (iii) such indemnifying party

shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.

(e)            EDGAR.

For purposes of this Section 7, all references to the Registration Statement, any preliminary prospectus, Issuer Free Writing

Prospectus or the Prospectus, or any amendment or supplement to any of the foregoing, shall be deemed to include, without limitation,

any electronically transmitted copies thereof filed with the Commission pursuant to EDGAR.

Section 8.                Contribution.

If the indemnification provided for in Section 7 hereof is for any reason unavailable to or insufficient to hold harmless an indemnified

party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute

to the aggregate amount of such losses, liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i) in

such proportion as is appropriate to reflect the relative benefits received by the Transaction Entities, on the one hand, and the Underwriters,

on the other hand, from the offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) is

not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause

(i) above but also the relative fault of the Transaction Entities, on the one hand, and of the Underwriters, on the other hand, in

connection with the statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as well as any other

relevant equitable considerations.

The relative benefits received by the Transaction

Entities, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Securities pursuant to this

Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant

to this Agreement (before deducting expenses) received by the Company, on the one hand, and the total underwriting discount received by

the Underwriters, on the other hand, in each case as set forth on the cover of the Prospectus, bear to the aggregate public offering price

of the Securities as set forth on the cover of the Prospectus.

The relative fault of the Transaction Entities,

on the one hand, and the Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue

or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied

by the Transaction Entities or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity

to correct or prevent such statement or omission.

The Transaction Entities and the Underwriters agree

that it would not be just and equitable if contribution pursuant to this Section 8 were determined by pro rata allocation (even if

the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the

equitable considerations referred to above in this Section 8. The aggregate amount of losses, liabilities, claims, damages and expenses

incurred by an indemnified party and referred to above in this Section 8 shall be deemed to include any legal or other expenses reasonably

incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding

by any governmental agency or body, domestic or foreign, commenced or threatened, or any claim whatsoever based upon any such untrue or

alleged untrue statement or omission or alleged omission.

Notwithstanding the provisions of this Section 8,

no Underwriter shall be required to contribute any amount in excess of the underwriting discount received by such Underwriter in connection

with the Securities underwritten by it and distributed to the public.

No person guilty of fraudulent misrepresentation

(within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any person who was not guilty of

such fraudulent misrepresentation.

For purposes of this Section 8, each director,

officer or agent of an Underwriter, and each person, if any, who controls an Underwriter within the meaning of Section 15 of the

1933 Act or Section 20 of the 1934 Act and each Underwriter’s Affiliates shall have the same rights to contribution as such

Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if

any, who controls either of the Transaction Entities within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934

Act shall have the same rights to contribution as the Transaction Entities. The Underwriters’ respective obligations to contribute

pursuant to this Section 8 are several in proportion to the number of Initial Securities set forth opposite their respective names

in Schedule A hereto and not joint.

Section 9.                Representations,

Warranties and Agreements to Survive. All representations, warranties and agreements contained in this Agreement, or contained in

certificates of officers or other representatives of either of the Transaction Entities or any of their subsidiaries or the Manager submitted

pursuant hereto, shall remain operative and in full force and effect, regardless of any investigation made by or on behalf of any Underwriter

or its Affiliates, its directors, officers or agents or any controlling person, or by or on behalf of either of the Transaction Entities

or the Manager and shall survive delivery and payment for the Securities to the Underwriters.

Section 10.             Termination

of Agreement.

(a)            Termination.

The Representatives may terminate this Agreement, by notice to the Transaction Entities, at any time at or prior to Closing Time (and,

if any Option Securities are to be purchased on a Date of Delivery which occurs after Closing Time, the Representatives may terminate

the obligation to purchase such Option Securities, by notice to the Transaction Entities, at any time on or prior to such Date of Delivery),

if (i) there has been since the time of execution of this Agreement or since the respective dates as of which information is given

in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition, financial

or otherwise, or in the earnings, business affairs or business prospects of the Transaction Entities and their subsidiaries considered

as one enterprise, whether or not arising in the ordinary course of business, (ii) there has occurred any material adverse change

in the financial markets in the United States or the international financial markets, any outbreak of hostilities or the escalation thereof

or other calamity or crisis or change or development involving a prospective change in national or international political, financial

or economic conditions, in each case the effect of which is such as to make it, in the judgment of the Representatives, impracticable

or inadvisable to proceed with the completion of the offering of the Securities or to enforce contracts for the sale of the Securities,

(iii) trading in any securities of the Company has been suspended or materially limited by the Commission or a national securities

exchange, or if trading generally on either the New York Stock Exchange or in the Nasdaq Global Market has been suspended or materially

limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices for securities have been required, by

the New York Stock Exchange or by the Nasdaq Global Market or by order of the Commission, FINRA or any other governmental agency or body,

or a material disruption has occurred in commercial banking or securities settlement or clearance services in the United States, or (iv) a

banking moratorium has been declared by either federal, New York or Maryland authorities.

(b)            Liabilities.

If this Agreement is terminated pursuant to this Section 10, such termination shall be without liability of any party to any other

party except as provided in Section 5 hereof. Notwithstanding any such termination, the provisions of Section 1, Section 7,

Section 8, Section 9, Section 13, Section 14, Section 19 and Section 20 shall remain in full force and effect.

Section 11.              Default

by One or More of the Underwriters. If one or more of the Underwriters shall fail at the Closing Time or a Date of Delivery, as the

case may be, to purchase the Securities which it or they are obligated to purchase under this Agreement (the “Defaulted Securities”),

the Representatives shall have the right, within 24 hours thereafter, to make arrangements for one or more of the non-defaulting Underwriters,

or any other underwriters, to purchase all, but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and

upon the terms herein set forth; if, however, the Representatives shall not have completed such arrangements within such 24-hour period,

then:

(a)            if

the number of Defaulted Securities does not exceed 10% of the total number of Securities to be purchased on such date, each of the non-defaulting

Underwriters shall be obligated, severally and not jointly, to purchase the full amount thereof in the proportions that their respective

underwriting obligations hereunder bear to the underwriting obligations of all non-defaulting Underwriters, or

(b)            if

the number of Defaulted Securities exceeds 10% of the total number of Securities to be purchased on such date, this Agreement or, with

respect to any Date of Delivery which occurs after the Closing Time, the obligation of the Underwriters to purchase, and the Company to

sell, the Option Securities to be purchased and sold on such Date of Delivery shall terminate without liability on the part of any non-defaulting

Underwriter.

No action taken pursuant to this Section 11

shall relieve any defaulting Underwriter from liability in respect of its default.

In the event of any such default which does not

result in a termination of this Agreement or, in the case of a Date of Delivery which is after the Closing Time, which does not result

in a termination of the obligation of the Underwriters to purchase and the Company to sell the relevant Option Securities, as the case

may be, either the (i) Representatives or (ii) the Company shall have the right to postpone Closing Time or the relevant Date

of Delivery, as the case may be, for a period not exceeding seven days in order to effect any required changes in the Registration Statement,

the General Disclosure Package or the Prospectus or in any other documents or arrangements. As used herein, the term “Underwriter”

includes any person substituted for an Underwriter under this Section 11.

Section 12.             Notices.

Unless otherwise provided herein, all notices required

under the terms and provisions hereof shall be in writing, either delivered by hand, by mail or by fax, and any such notice shall be effective

when received at the address specified below.

If to the Transaction Entities:

Janus Living, Inc. / Janus Living OP, LLC

4600 South Syracuse Street, Suite 500

Denver, Colorado 80237

Attention: Tracy Porter and Ankit Patadia

Email:

With a copy (which shall not constitute notice)

to:

Lewis K. Kneib, Esq.

Devon L. MacLaughlin, Esq.

Latham & Watkins LLP

10250 Constellation Blvd., Suite 1100

Los Angeles, California 90067

Email:

If to the Manager:

Healthpeak Investment Management, LLC

c/o Healthpeak Properties, Inc.

4600 South Syracuse Street, Suite 500

Denver, Colorado 80237

Attention: Tracy Porter and Ankit Patadia

Email:

With a copy (which shall not constitute notice)

to:

Lewis K. Kneib, Esq.

Devon L. MacLaughlin, Esq.

Latham & Watkins LLP

10250 Constellation Blvd., Suite 1100

Los Angeles, California 90067

Email:

If to the Underwriters:

BofA Securities, Inc.

One Bryant Park

New York, New York 10036

Attention: Syndicate Department

Email:

and a copy to

BofA Securities, Inc.

One Bryant Park

New York, New York 10036

Attention: ECM Legal

Email:

J.P. Morgan Securities LLC

270 Park Avenue

New York, New York 10017

Fax: (212) 622-8358

Attention: Equity Syndicate Desk

RBC Capital Markets, LLC

200 Vesey Street, 8th Floor

New York, New York 10281

Attention: Equity Capital Markets

Wells Fargo Securities, LLC

500 West 33rd Street

New York, New York 10001

Attention: Equity Syndicate Department

Fax: (212) 214-5918

With a copy (which shall not constitute notice)

to:

J. Gerard Cummins, Esq.

Adam M. Gross, Esq.

Sidley Austin LLP

787 Seventh Avenue

New York, New York 10019

Email:

or at such other address as such party may designate from time to time

by notice duly given in accordance with the terms of this Section 12.

Section 13.              Parties.

This Agreement shall each inure to the benefit of and be binding upon the Underwriters, the Transaction Entities and the Manager and their

respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or

corporation, other than the Underwriters, the Transaction Entities and the Manager and their respective successors and the controlling

persons and the agents, officers and directors referred to in Section 7 and Section 8 hereof and their heirs and legal representatives

any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision herein contained. This Agreement

and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Underwriters, the Transaction Entities

and the Manager and their respective successors, and said controlling persons and said agents, officers and directors and their heirs

and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from any Underwriter

shall be deemed to be a successor merely by reason of such purchase.

Section 14.              Governing

Law.THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY, AND

CONSTRUED IN ACCORDANCE WITH, THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.

Section 15.              TIME.

TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.

Section 16.              Recognition

of the U.S. Special Resolution Regimes.

(a)            In

the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer

from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent

as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were

governed by the laws of the United States or a state of the United States.

(b)            In

the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under

a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to

be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement

were governed by the laws of the United States or a state of the United States.

purposes of this Section 16: (A) a “BHC Act Affiliate” has the meaning assigned to the term “affiliate”

in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k); (B) “Covered Entity” means

any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12

C.F.R. § 252.82(b); (ii) a “covered bank” as that term is defined in, and interpreted in accordance

with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined in, and interpreted

in accordance with, 12 C.F.R. § 382.2(b); (C) “Default Right” has the meaning assigned to that

term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable; and (D) “U.S.

Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder

and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

Section 17.              No

Advisory or Fiduciary Relationship. Each of the Transaction Entities and the Manager acknowledges and agrees that (a) the purchase

and sale of the Securities pursuant to this Agreement, including the determination of the public offering price of the Securities and

any related discounts and commissions, is an arm’s-length commercial transaction between the Transaction Entities, Healthpeak and

the Manager, on the one hand, and the several Underwriters, on the other hand, and does not constitute a recommendation, investment advice,

or solicitation of any action by the Underwriters, (b) in connection with the offering of the Securities and the process leading

thereto, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of either of the Transaction

Entities or the Manager, any of their subsidiaries or other affiliates, or their respective stockholders, creditors, employees or any

other party, (c) no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Transaction Entities

or the Manager or any of their subsidiaries or other affiliates with respect to the offering of the Securities or the process leading

thereto (irrespective of whether such Underwriter has advised or is currently advising either of the Transaction Entities or the Manager

or any of their subsidiaries or other affiliates on other matters) and no Underwriter has any obligation to the Transaction Entities or

the Manager or any of their subsidiaries or other affiliates with respect to the offering of the Securities except the obligations expressly

set forth in this Agreement, (d) the Underwriters and their respective affiliates may be engaged in a broad range of transactions

that involve interests that differ from those of each of the Transaction Entities, the Manager and their subsidiaries or other affiliates,

and (e) the Underwriters have not provided any legal, accounting, regulatory, investment or tax advice with respect to the offering

of the Securities and each of the Transaction Entities, the Manager and their subsidiaries or other affiliates has consulted its own respective

legal, accounting, financial, regulatory and tax advisors to the extent it deemed appropriate, and (f) none of the activities of

the Underwriters in connection with the transactions contemplated herein constitutes a recommendation, investment advice or solicitation

of any action by the Underwriters with respect to any entity or natural person.

Section 18.              Entire

Agreement. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Transaction Entities,

Healthpeak, the Manager and the Underwriters, or any of them, with respect to the subject matter hereof.

Section 19.              Waiver

of Jury Trial. Each of the Transaction Entities, the Manager and the Underwriters hereby irrevocably waives, to the fullest extent

permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or

the transactions contemplated hereby.

Section 20.              Consent

to Jurisdiction. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated

hereby shall be instituted in (i) the federal courts of the United States of America located in the City and County of New York,

Borough of Manhattan or (ii) the courts of the State of New York located in the City and County of New York, Borough of Manhattan

(collectively, the “Specified Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for

proceedings instituted in regard to the enforcement of a judgment of any such court, as to which such jurisdiction is non-exclusive) of

such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s

address set forth above shall be effective service of process for any suit, action or proceeding brought in any such court. The parties

irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or proceeding in the Specified Courts and

irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or proceeding brought

in any such court has been brought in an inconvenient forum.

Section 21.              Counterparts

and Electronic Signatures. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original,

but all such counterparts shall together constitute one and the same Agreement. Electronic signatures complying with the New York Electronic

Signatures and Records Act (N.Y. State Tech. §§ 301-309), as amended from time to time, or other applicable law will be deemed

original signatures for purposes of this Agreement. Transmission by telecopy, electronic mail or other transmission method of an executed

counterpart of this Agreement will constitute due and sufficient delivery of such counterpart.

Section 22.              Severability.

The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability

of any other Section, paragraph or provision hereof or thereof, as the case may be. If any Section, paragraph or provision of this Agreement

is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor

changes) as are necessary to make it valid and enforceable.

Section 23.              Effect

of Headings. The Section headings herein are for convenience only and shall not affect the construction hereof.

[Signature page follows.]

If the foregoing is in accordance with your understanding

of our agreement, please sign and return to the Company, the Operating Company and the Manager a counterpart hereof, whereupon this instrument,

along with all counterparts, will become a binding agreement among the Underwriters, the Company, the Operating Company and the Manager

in accordance with its terms.

Very truly yours,

Janus Living, Inc.

By:

/s/ Kelvin O. Moses

Name: Kelvin O. Moses

Title: Chief Financial Officer

Janus Living OP, LLC

By: Janus Living, Inc., its managing member

By:

/s/ Kelvin O. Moses

Name: Kelvin O. Moses

Title: Chief Financial Officer

Healthpeak Investment Management, LLC

By:

/s/ Adam G. Mabry

Name: Adam G. Mabry

Title: Chief Investment Officer

[Signature

Pages to Underwriting Agreement]

CONFIRMED AND ACCEPTED,

as of the date first above written:

BOFA SECURITIES, INC.

By:

/s/ Gray Hampton

Name: Gray Hampton

Title: Vice Chairman

J.P. Morgan Securities LLC

By:

/s/ Grace Schlesinger

Name: Grace Schlesinger

Title: Vice President

RBC Capital Markets, LLC

By:

/s/ Asad Kazim

Name: Asad Kazim

Title: Managing Director Group Head, U.S. Real Estate

Wells Fargo Securities, LLC

By:

/s/ Rohit Mehta

Name: Rohit Mehta

Title: Managing Director

For themselves and as Representatives of the other

Underwriters named in Schedule A hereto.

[Signature

Pages to Underwriting Agreement]

SCHEDULE A

The public offering price per share for the Securities shall be $25.00.

The purchase price per share for the Securities to be paid by the several

Underwriters shall be $24.0625, being an amount equal to the public offering price set forth above less $0.9375 per share, subject to

adjustment in accordance with Section 2(b) for dividends or distributions declared by the Company and payable on the Initial

Securities but not payable on the Option Securities.

Name of Underwriter

Number of Initial

Securities

BofA Securities, Inc.

6,132,500

J.P. Morgan Securities LLC

5,100,000

RBC Capital Markets, LLC

3,032,500

Wells Fargo Securities, LLC

3,032,500

Goldman Sachs & Co. LLC

1,282,500

Morgan Stanley & Co. LLC

1,282,500

Barclays Capital Inc.

1,167,500

Jefferies LLC

1,167,500

KeyBanc Capital Markets Inc.

1,167,500

TD Securities (USA) LLC

1,167,500

Credit Agricole Securities (USA) Inc.

162,500

Regions Securities LLC

117,500

Santander US Capital Markets LLC

117,500

Capital One Securities, Inc.

70,000

Total

25,000,000

Schedule A-1

SCHEDULE B-1

Pricing Terms

1.            The

Company is selling 25,000,000 shares of Class A-1 Common Stock.

2.            The

Company has granted an option to the Underwriters, severally and not jointly, to purchase up to an additional 3,750,000 shares of Class A-1

Common Stock.

3.            The

public offering price per share for the Securities shall be $25.00.

Schedule B-1-1

SCHEDULE B-2

Free Writing Prospectuses

None

Schedule B-2-1

EXHIBIT A

Opinion and Negative Assurance Letter of Latham &

Watkins LLP

[INTENTIONALLY OMITTED]

Tax Opinion of Latham & Watkins LLP

[INTENTIONALLY OMITTED]

Exhibit A-1

EXHIBIT B

Opinion of Ballard Spahr LLP

[INTENTIONALLY OMITTED]

Exhibit B-1

EXHIBIT C

Form of Lock-Up

[●], 2026

BofA Securities, Inc.

One Bryant Park

New York, New York 10036

J.P. Morgan Securities LLC

270 Park Avenue

New York, New York 10017

RBC Capital Markets, LLC

200 Vesey Street, 8th Floor

New York, New York 10281

Wells Fargo Securities, LLC

500 West 33rd Street, 14th Floor

New York, New York 10001

As Representatives of the Several Underwriters

Re:                Proposed

Public Offering by Janus Living, Inc.

Dear Ladies and Gentlemen:

The undersigned,

a stockholder and/or an officer and/or a director and/or the external manager of Janus Living, Inc., a Maryland corporation (the

“Company”), understands that BofA Securities, Inc. (“BofA”), J.P. Morgan Securities LLC (“J.P.

Morgan”), RBC Capital Markets, LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters (the “Representatives”),

propose to enter into an underwriting agreement (the “Underwriting Agreement”) with the Company, Janus Living OP, LLC,

a Maryland limited liability company (the “Operating Company”), and Healthpeak Investment Management, LLC, a Delaware

limited liability company and the Company’s external manager (the “Manager”), providing for the public offering

(the “Offering”) of shares (the “Securities”) of the Company’s Class A-1 common stock,

par value $0.01 per share (the “Class A-1 Common Stock”). In recognition of the benefit that the Offering will

confer upon the undersigned as a stockholder and/or an officer and/or a director and/or the Manager, as applicable, of the Company, and

for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned agrees with each

underwriter to be named in the Underwriting Agreement that, during the period beginning on the date hereof and ending on the date that

is 90 days from the date of the Underwriting Agreement (the “Lock-Up Period”), the undersigned will not, without

the prior written consent of BofA and J.P. Morgan (the “Lock-up Release Parties”), (i) offer, pledge, sell, contract

to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase,

lend or otherwise dispose of or transfer, directly or indirectly, any shares of the Company’s Class A-1 Common Stock or any

securities convertible into or exchangeable or exercisable for Class A-1 Common Stock (including, without limitation, membership

interests in the Operating Company), whether now owned or hereafter acquired by the undersigned or with respect to which the undersigned

has or hereafter acquires the power of disposition (including, without limitation, Class A-1 Common Stock or such other securities

which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the U.S. Securities

and Exchange Commission (the “Commission”) and securities which may be issued upon exercise of a stock option or warrant)

(collectively, the “Lock-Up Securities”), or exercise any right with respect to the registration of any of the Lock-Up

Securities, or file, cause to be filed or cause to be confidentially submitted any registration statement in connection therewith, under

the Securities Act of 1933, as amended (the “Securities Act”) or (ii) enter into any hedging, swap, loan or any

other agreement or any transaction (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or

call option, or combination thereof, forward or any other derivative transaction or instrument, however described or defined) that transfers,

in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such hedging,

swap, loan or transaction is to be settled by delivery of Class A-1 Common Stock or other securities, in cash or otherwise, or (iii) publicly

disclose the intention to do any of the foregoing described in clauses (i) and (ii) above.

Exhibit C-1

Notwithstanding the

foregoing, and subject to the conditions below, the undersigned may transfer the Lock-Up Securities without the prior written consent

of the Lock-up Release Parties, as described below, provided that (1) in the case of clause (i), (ii), (v), (vi) (to the extent

in relation to clause (i), (ii) or (v)), (vii) or (viii), the Lock-up Release Parties receive a signed lock-up agreement in

the form of this lock-up agreement for the balance of the Lock-Up Period from each donee, devisee, trustee, distributee, or transferee,

as the case may be, (2) in the case of clauses (i), (vii) or (viii)(B), any such transfer shall not involve a disposition for

value, (3) such transfers are not required to be reported during the Lock-Up Period with the Commission on Form 4 or Form 5

in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

or, in the case of clause (i), (ii), (iii), (iv), (x) or (xi) below, any such required filing shall clearly indicate in the

footnotes thereto that the filing relates to circumstances described in such a clause, and (4) the undersigned does not otherwise

voluntarily effect any public filing or report regarding such transfers:

(i) as a bona fide gift or gifts, including, without limitation, to a charitable organization or educational institution, or for

bona fide estate planning purposes;

(ii) by will, testamentary document or intestate succession to the legal representative, heir, beneficiary

or a member of the immediate family of the undersigned (for purposes of this lock-up agreement, “immediate family”

of the undersigned shall mean any relationship by blood, marriage, domestic partnership or adoption, not more remote than first cousin

of the undersigned);

(iii) by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement;

Exhibit C-2

(iv) pursuant to an order of a court or regulatory agency having jurisdiction over the undersigned;

(v) to any corporation, partnership, limited liability company or other entity of which the undersigned or the immediate family of the

undersigned are the legal and beneficial owner of all of the outstanding equity securities or similar interests;

(vi) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through

(v) above;

(vii) to any immediate family member or any trust, partnership, limited liability company or other entity for the direct or indirect benefit

of the undersigned or one or more immediate family members of the undersigned, or if the undersigned is a trust, to a trustor or beneficiary

of the trust or to the estate of a beneficiary of such trust;

(viii) if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (A) to another corporation,

partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under

the Securities Act) of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or

under common control with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned

is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as

part of a distribution to limited partners, limited liability company members or stockholders of the undersigned or holders of similar

equity interests in the undersigned;

(ix) to the Company upon the undersigned’s death, disability or termination of employment or other service relationship with the

Company; provided that such shares of Class A-1 Common Stock were issued to the undersigned pursuant to an agreement or equity

award granted pursuant to an employee benefit plan, option, warrant or other right disclosed in the prospectus for the Offering;

(x) to the Company or the Operating Company pursuant to (A) the exercise on a net issuance basis by the undersigned of any award

granted pursuant to the Company’s employee benefit plans as described in the prospectus for the Offering, or (B) share withholdings

to cover applicable taxes in connection with the vesting or settlement of any award granted pursuant to the Company’s employee benefit

plans as described in the prospectus for the Offering;

(xi) to the Company or the Operating Company pursuant to any redemption, exchange or conversion right relating

to membership interests in the Operating Company or any equity interests in any other subsidiary of the Company, including any

cancellation of Class A-2 common stock of the Company in connection with any such redemption, exchange or conversion; or

Exhibit C-3

(xii) to a bona fide third party pursuant to a merger, consolidation, tender offer or other similar transaction pursuant to an offer made

to all holders of Class A-1 Common Stock and involving a change of control of the Company (for purposes of this clause (xii), “change

of control” shall mean the transfer (whether by merger, consolidation, tender offer or other similar transaction), in one transaction

or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such

person or group of affiliated persons would hold at least a majority of the outstanding voting securities of the Company (or the surviving

entity)) and approved by the Company’s board of directors; provided that in the event that such merger, consolidation, tender offer

or other similar transaction is not completed, the undersigned’s Lock-Up Securities shall remain subject to the provisions of this

lock-up agreement.

Furthermore, the undersigned may sell shares of

Class A-1 Common Stock of the Company purchased by the undersigned on the open market following the Offering if and only if (i) such

sales are not required to be reported in any public report or filing with the Commission or otherwise and (ii) the undersigned does

not otherwise voluntarily effect any public filing or report regarding such sales.

The undersigned acknowledges

and agrees that the underwriters have neither provided any recommendation or investment advice nor solicited any action from the undersigned

with respect to the Offering of the Class A-1 Common Stock and the undersigned has consulted their own legal, accounting, financial,

regulatory and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the

underwriters may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection

with the Offering, the underwriters are not making a recommendation to you to enter into this lock-up agreement and nothing set forth

in such disclosures is intended to suggest that any underwriter is making such a recommendation.

The undersigned hereby represents and warrants

that the undersigned has full power, capacity and authority to enter into this lock-up agreement. The undersigned understands that the

Company and the underwriters are relying upon the lock-up agreement in proceeding toward the consummation of the Offering. The undersigned

further understands that this lock-up agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives,

successors and assigns.

In the event that a Lock-up Release Party withdraws

or is terminated from, or declines to participate in, the Offering, all references in this lock-up agreement to the Lock-up Release Parties

shall refer to the remaining Lock-up Release Party. If all Lock-up Release Parties withdraw, are terminated from or decline to participate

in the Offering, all references in this lock-up agreement to the Lock-up Release Parties shall refer to the lead left book runner in the

Offering (“Replacement Entity”), and in such event, any written consent, waiver or notice given or delivered in connection

with this lock-up agreement by or to such Replacement Entity shall be deemed to be sufficient and effective for all purposes under this

lock-up agreement.

Exhibit C-4

Notwithstanding anything to the contrary contained

herein, this lock-up agreement will automatically terminate and the undersigned will be released from all of their or its obligations

hereunder upon the earliest to occur, if any, of the following: (i) prior to the execution of the Underwriting Agreement, the Company

advises the Representatives in writing that it has determined not to proceed with the Offering, (ii) the Company files an application

with the Commission to withdraw the registration statement relating to the Offering, (iii) the Underwriting Agreement is executed

but is terminated (other than with respect to the provisions thereof which survive termination) prior to payment for and delivery of the

Class A-1 Common Stock to be sold thereunder or (iv) September 30, 2026 in the event that the Offering shall not have occurred

on or before such date (provided that the Company may, by written notice to the undersigned prior to such date, extend such date for a

period of up to an additional three months).

This lock-up agreement shall be governed by and

construed in accordance with the laws of the State of New York.

This lock-up agreement may be executed in any number

of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same

lock-up agreement. Electronic signatures complying with the New York Electronic Signatures and Records Act (N.Y. State Tech. §§

301-309), as amended from time to time, or other applicable law will be deemed original signatures for purposes of this lock-up agreement.

Transmission by telecopy, electronic mail or other transmission method of an executed counterpart of this lock-up agreement will constitute

due and sufficient delivery of such counterpart.

[SIGNATURE PAGE FOLLOWS]

Exhibit C-5

Very truly yours,

[NAME OF STOCKHOLDER / OFFICER/ DIRECTOR / MANAGER]

By:

Name:

Title:

If not signing in an individual capacity:

Name of Authorized Signatory (Print)

Title of Authorized Signatory (Print)

(Indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity.)

[Signature

Page to Lock-Up Agreement]

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jun. 02, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 02, 2026

Entity File Number

001-43206

Entity Registrant Name

Janus Living, Inc.

Entity Central Index Key

0002100805

Entity Tax Identification Number

41-2996951

Entity Incorporation, State or Country Code

Entity Address, Address Line One

4600

South Syracuse Street

Entity Address, Address Line Two

Suite 500

Entity Address, City or Town

Denver

Entity Address, State or Province

Entity Address, Postal Zip Code

80237

City Area Code

720

Local Phone Number

428-5050

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Class A-1 Common Stock,

$0.01 par value

Trading Symbol

JAN

Security Exchange Name

NYSE

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration